

BMJ Open

Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts All-Cause Mortality and Cardiovascular Events in a Community-Dwelling Population

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013431
Article Type:	Research
Date Submitted by the Author:	14-Jul-2016
Complete List of Authors:	Xiao, Wenkai Ye, Ping; Chinese PLA General Hospital, Geriatric Cardiology Cao, Ruihua; Chinese PLA General Hospital, Geriatric Cardiology Liu, Yuan; Chinese PLA General Hospital, Geriatric Cardiology Bai, Yongyi; Chinese PLA General Hospital, Geriatric Cardiology Wu, Hongmei; Chinese PLA General Hospital, Geriatric Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Public health
Keywords:	Biomarkers, Cardiac Epidemiology < CARDIOLOGY, risk assessment, prognosis

SCHOLARONE™
Manuscripts

1
2
3
4 **Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts**
5
6 **All-Cause Mortality and Cardiovascular Events in a**
7
8
9 **Community-Dwelling Population**
10

11
12
13
14 Wenkai Xiao, Ping Ye *, Ruihua Cao, Yuan Liu , Yongyi Bai , Hongmei Wu

15
16 Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28, Fuxing
17
18 Road, Beijing, 100853, China
19

20
21 Correspondence to Ping Ye, Department of Geriatric Cardiology, Chinese PLA
22
23 General Hospital, Beijing, 100853, China
24

25
26 Tel:+86-10-66876369; Fax:+86-10-66876349; E-mail: yeping301@sina.com
27

28
29 **Keywords:** Biomarkers; High-sensitivity cardiac troponin T; cardiovascular diseases;
30
31 prognosis; risk assessment.
32

33
34 **Word count:** 5273
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: The prognostic value of cardiac troponins in apparently healthy population is less well established. The aim of this study is to investigate the prognostic properties of high-sensitivity cardiac troponin T (hs-cTnT) for long-term adverse outcomes.

Setting: A community-dwelling prospective survey of residents from two communities in Beijing.

Participants: From September 2007 to January 2009, 1680 participants were initially enrolled, 1,499 (870 females, mean age 61.4 years) completed and were followed up for a median of 4.8 years (interquartile range, 4.5-5.2).

Outcome measures: primary outcomes were the occurrence of all-cause mortality and major cardiovascular events.

Results: In total, 820 individuals (54.7%) had detectable hs-cTnT levels. During follow-up, 52 participants (3.5%) died, 154 (10.3%) had major cardiovascular events, and 99 (6.6%) experienced new-onset coronary events. Compared with participants with undetectable levels, those with hs-cTnT levels in the highest category (≥ 14 ng/L) had significantly increased risk for all-cause mortality (adjusted hazard ratio [aHR] = 2.07; 95% confidence interval [CI], 1.05 to 3.01), major cardiovascular events (aHR = 3.27; 95% CI, 1.88 to 5.70), and coronary events (aHR = 4.50; 95% CI, 2.26 to 9.02) but not of stroke incident (aHR = 1.27; 95% CI, 0.69 to 2.62) in covariate-adjusted analyses accounting for demographics, traditional cardiovascular risk factors, renal function, and biomarkers of inflammation and cardiac wall stress. Also the significant

1
2
3
4 associations were presented when hs-cTnT levels were modeled as a continuous
5
6 variable and when analyzing changes over time in the hs-cTnT levels with adverse
7
8 outcomes.
9

10
11 **Conclusions:** In this cohort of individuals from community-based population,
12
13 cardiac troponin T measured with a highly sensitive assay was associated with
14
15 subsequent risk for all-cause mortality and major cardiovascular events, which might
16
17 support selection of at risk individuals.
18
19

20 21 22 23 **Strengths and limitations of this study**

- 24
25 ■ Evaluating the prognostic properties of both baseline and change in hs-cTnT for
26
27 long-term adverse outcomes in a large community-dwelling study.
28
29
- 30
31 ■ Reliably detecting minimal subclinical myocardial injury in apparently healthy
32
33 population over a wide age range.
34
35
- 36
37 ■ Absence of echocardiographic and coronary artery imaging data and can, thus,
38
39 not provide causal explanations on the associations between hs-cTnT and
40
41 outcomes.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Cardiovascular disease (CVD) is still the major disease which seriously threat to human's health and lives. There is concordant evidence that prevention is an important key to lessen the CVD burden, but the risk prediction of adverse cardiovascular events in low- to intermediate-risk individuals is an important challenge.[1] This part of population are at risk for developing CVD but not early identified by currently risk factors screening methods.[2-3] While circulating biomarkers are an important supplement, one of the most interesting biomarkers in this context is troponins. Cardiac troponin T (cTnT) is a regulatory protein expressed by cardiac myocytes and released in the setting of myocardial injury.[4-5] A sensitive and specific marker of cardiomyocytes damage, cTnT is typically used clinically in the earlier exclusion or confirmation of the diagnosis of acute myocardial infarction (AMI).

However, cTnT levels can also be elevated and clinically meaningful in the absence of myocardial ischemia. Detectable levels of cTnT can also be useful for detecting subclinical CVD and assessing CVD risk in the general population; however, cTnT is only detectable in a small percentage of the general population using standard assays,[6-7] which limit the utility for our clinical applications. Recently, a highly sensitive cTnT (Hs-cTnT) assay has been developed, which can detect 10-fold lower concentrations than the standard fourth-generation assay. The introduction of this new assay has enabled detection of very low levels of circulating cTnT, even in some asymptomatic general population.[8]

Hs-cTnT levels below the detection limit of standard assays were independently

1
2
3 associated with adverse cardiovascular events in patients with heart failure (HF)[9] or
4 stable coronary heart disease (CHD).[10] But the clinical significance of detectable
5
6 cTnT with the use of the new assay in the apparently healthy population is less well
7
8 established. The main objective of this study was to investigate the prognostic value
9
10 of minimally detectable hs-cTnT levels in predicting adverse clinical events in a
11
12 population of community-based subjects.
13
14
15
16
17
18

19 **Methods**

20 **Study population**

21
22 This is a prospective observational study of people living in the Pingguoyuan
23
24 area of the Shijingshan district in Beijing, China. Subjects with severe systemic
25
26 diseases such as immunologic diseases, endocrinic and metabolic disease (except for
27
28 diabetes mellitus [DM]), inflammation, tumorous, severe hepatic or renal diseases,
29
30 and a history of ischemic heart disease or HF were excluded. Briefly, between
31
32 September 2007 and January 2009, a total of 1680 participants were initially recruited
33
34 for cross-sectional analysis of CVD risk factors. After the initial evaluation, recruited
35
36 subjects were contacted every 2 years for follow-up, and the last follow-up visits were
37
38 conducted through September 30, 2013, the median follow-up was 4.8 (interquartile
39
40 range 4.5-5.2) years. In our investigation, 181 participants were lost to follow-up and
41
42 were excluded from the study, complete data were acquired from 1499 participants
43
44 (return rate, 89.2%). All participants provided written informed consent at time of
45
46 enrollment, and the study was approved by the Ethics Committee of the Chinese
47
48 People's Liberation Army (PLA) General Hospital.
49
50
51
52
53
54
55
56
57
58
59
60

Data collection

Baseline characteristics for this analysis were collected using self-reported standardized questionnaires that included demographics, life-style information, medical history, and medication use. Anthropometrical measurements were obtained by trained medical doctors, and the body mass index (BMI) was derived from height and weight measured with participants wearing light clothing and no shoes. Blood pressures were measured two times on the right arm after 5 minutes of rest in a sitting position, the mean of 2 readings were used for further analysis. Participants were followed up for clinical outcomes by interview. Outcome measures were occurrences of all-cause mortality and major adverse cardiovascular event (MACE), new events were validated by obtaining medical records and adjudicated by 2 independent and blinded reviewers.

Biomarker Assays

After at least 12 hours of overnight fasting, baseline blood samples were collected from participants between 8 AM and 10 AM at enrollment. Follow-up measurements were performed on blood samples collected 4 to 5 years later. Serum aliquots were frozen at -80°C until analysis in a central laboratory were performed. Concentrations of blood glucose (fasting and 2 hours after an oral glucose tolerance), total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid and serum creatinine levels were measured by routine laboratory analysis.

Hs-cTnT were measured by an electrochemiluminescence immunoassay method

1
2
3
4 using an Elecsys Troponin T highly sensitive assay (Roche Diagnostics GmbH,
5
6 Mannheim, Germany) on the Modular Analytics E170 autoanalyzer (Roche
7
8 Diagnostics). The lower detection limit of the novel assay was 3 ng/L and a reported
9
10 99th percentile value in apparently healthy individuals was 14 ng/L.[11] N-terminal
11
12 pro-B-type natriuretic peptide (NT-proBNP) concentrations were determined using an
13
14 electrochemiluminescence immunoassay (Roche Diagnostics GmbH) on the Roche
15
16 analyzer. Levels of high-sensitivity C-reactive protein (hs-CRP) were measured with
17
18 the use of immunoturbidimetric assay (Siemens Healthcare Diagnostics, IN, USA) on
19
20 a Dimension RxL Max analyzer (Siemens Healthcare Diagnostics).
21
22
23
24

25
26 Estimated glomerular filtration rate (eGFR) was calculated using the Chinese
27
28 modifying Modification of Diet in Renal Disease (C-MDRD) equation, details of the
29
30 computing equation have been published elsewhere.[12]
31
32

33 34 **Definition of end points**

35
36 For outcome, we used the incidence of mortality and CVD morbidity after the
37
38 baseline screening. All-cause mortality was determined by review of death certificates.
39
40 The definition of MACE comprised nonfatal MI, coronary artery insufficiency
41
42 (identified by coronary artery imaging or receiving coronary revascularization), stroke
43
44 (ischaemic or haemorrhagic), and CVD death. Major coronary events were defined as
45
46 nonfatal MI, coronary artery insufficiency, and CHD death. Stroke was characterized
47
48 as a neurological deficit attributed to an acute focal injury of the central nervous
49
50 system by a vascular cause, including cerebral infarction, intracerebral hemorrhage,
51
52 and subarachnoid hemorrhage. [13] For Cox-regression analyses, survival time was
53
54
55
56
57
58
59
60

1
2
3
4 defined as the period from the date of baseline blood sample collection to the date of
5
6 the first adverse event or end of follow-up.
7

8 9 **Statistical analysis**

10
11 Continuous variables are reported as mean \pm standard deviation (SD) or median
12
13 (interquartile range) and categorical variables as count and percentages. We modeled
14
15 hs-cTnT as both a categorical and a continuous variable. For the analyses of hs-cTnT
16
17 as a categorical variable, we divided participants into 4 categories: those with
18
19 undetectable hs-cTnT were placed in the first category as the reference group; those
20
21 with hs-cTnT levels greater than or equal to the previously reported 99th percentile
22
23 value (14 ng/L)[11] were placed in the fourth category, and those with levels between
24
25 3 and 14 ng/L were divided into two equal-sized groups for categories 2 and 3.
26
27 Demographic and clinical variables were compared across hs-cTnT categories using
28
29 the one-way analysis of variance tests for continuous measures, Cuzik's
30
31 nonparametric trend test for nonnormally distributed variables, and chi-squared tests
32
33 were performed for categorical variables.
34
35
36
37
38
39

40
41 Cumulative incidence of MACE and all-cause mortality for each category of
42
43 hs-cTnT concentration was evaluated using the Kaplan-Meier method and compared
44
45 with the log-rank test for trend. Multivariable Cox proportional hazards regression
46
47 models were used to analyze associations of hs-cTnT categories with outcomes with
48
49 category 1 used as the referent. The models were serially adjusting for demographics,
50
51 traditional cardiovascular risk factors, renal function and other biomarkers (Hs-CRP
52
53 and NT-proBNP) levels. We also carried an exploratory analysis in which we regarded
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

hs-cTnT as a continuous variable and assessed the relationship between natural logarithm transformed hs-cTnT values and end points. In this analysis, values of hs-TnT that were below the lower limit of detection were assigned to 1.5 ng/L (i.e., one-half of the lower limit of detection).

In view of the markedly skewed distribution of hs-cTnT, changes in concentrations over time were calculated as the difference between the natural logarithm of the concentrations at follow-up and at baseline. The association between changes in hs-cTnT levels and outcomes were also evaluated in Cox proportional hazards models. The change in hs-cTnT levels was entered as a continuous variable and adjusted for baseline concentration of hs-cTnT and for the relevant variables described previously in multivariable models.

All data were analyzed using the SPSS statistical package software (version 17.0). A two-sided value of $P < 0.05$ was considered statistically significant.

Results

Participant Characteristics

For the present analyses, 1499 participants were included. The mean (\pm SD) age of participants was 61.4 ± 11.4 years and 58.0% were women at enrollment. Hs-cTnT was detectable at baseline in 820 individuals (54.7%) and was equal to or higher than 14 ng/L in 172 participants (11.5%), the detectable hs-cTnT levels ranged from 3 to 176.4 ng/L. Table 1 shows baseline characteristics by hs-cTnT categories. Compared with those with lower hs-cTnT levels, individuals with higher levels were older; were more likely to be male, more frequently hypertensive, and diabetic; had lower eGFR,

1
2
3 HDL-C levels; and had higher uric acid, NT-proBNP levels. In cardiovascular drug
4
5 use, taking of antihypertensive, antidiabetic, and aspirin use varied across levels of
6
7
8
9 hs-cTnT.

10 11 **Outcomes by Baseline Hs-cTnT Level**

12
13
14 Over a median follow-up period of 4.8 years (interquartile range, 4.5-5.2), 154
15
16 participants experienced new-onset MACE (including 99 coronary events and 61
17
18 strokes, some participants had more than one event) and 52 deaths occurred from any
19
20 cause. The cumulative incidence of MACE and all-cause mortality by hs-cTnT
21
22 categories are shown in Figure 1. Just like display in the Kaplan-Meier survival
23
24 analysis, there was a graded increase in the probability of adverse clinical events
25
26 across the categories. The unadjusted incidence rate for MACE ranged from 3.7% in
27
28 those participants with undetectable hs-cTnT levels to 23.3% for subjects in the
29
30 highest category (P<0.001, log-rank test). Similar trends were discovered for coronary
31
32 events, stroke, and all-cause mortality, with a particularly high risk found for those in
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 the highest category.

Table1. Characteristics of Study Population by Baseline high-sensitivity troponin T Levels

Characteristics	Hs-cTNT Group (ng/L)				P value
	Group 1 <3.00 (n = 679)	Group 2 3.00-6.21 (n=324)	Group 3 6.22-<14 (n= 324)	Group4 ≥14 (n = 172)	
Demographic					
Age (years)	58.6±10.3	63.1±10.7	64.2±12.4	61.8±11.5	<0.001
Male Sex n (%)	202 (29.7)	163 (50.3)	170 (52.5)	94 (54.7)	<0.001
BMI (kg/m ²)	25.5±3.5	25.7±3.2	25.6±3.3	25.8±3.5	0.498
Medical history					
Hypertension n (%)	258 (38.0)	159 (49.1)	176 (54.3)	97 (56.4)	<0.001
Diabetes mellitus n (%)	99 (14.6)	72 (22.2)	76 (23.5)	45 (26.2)	<0.001
Current smoking n (%)	85 (12.5)	69 (21.3)	62 (19.1)	31(18.0)	0.003
Systolic BP (mm Hg)	131.5±16.5	132.7±17.3	132.8±17.2	133.2±17.1	0.041
Diastolic BP (mm Hg)	77.1±9.7	77.3±10.0	76.4±10.5	76.1±11.1	0.372
Laboratory values					
FBG (mmol/L)	5.3±1.4	5.3±1.5	5.5±1.7	5.8±1.9	0.076
PBG (mmol/L)	7.5±3.7	7.1±3.2	8.1±4.3	8.9±4.4	<0.001

Total cholesterol (mmol/L)	5.1±0.9	5.1±0.9	5.1±0.9	5.0±0.9	0.464
Triglycerides (mmol/L)	1.8±1.1	1.7±1.1	1.7±1.0	2.0±1.4	0.04
LDL cholesterol (mmol/L)	3.0±0.7	2.9±0.7	3.0±0.7	3.0±0.7	0.136
HDL cholesterol (mmol/L)	1.4±0.4	1.4±0.3	1.3±0.4	1.3±0.4	0.001
Uric acid (µmol/L)	279.0±68.2	295.9±73.3	301.2±75.4	309.5±76.2	<0.001
eGFR (mL/min/1.73m ²)	90.1±14.5	88.7±13.4	87.5±15.2	84.7±16.5	0.001
NT-proBNP (pg/mL)	37.2 (17.9, 75.3)	38.9 (17.9, 74.4)	46.6 (22.3, 90.1)	49.3 (17.1, 112)	0.003
Hs-CRP (mg/L)	2.4 (1.3, 3.4)	2.3 (1.4, 3.4)	2.2 (1.5, 3.5)	2.4 (1.6, 3.6)	0.383
Medication use					
Antihypertensives n (%)	187 (27.5)	122 (37.7)	139 (42.9)	80 (46.5)	<0.001
Antidiabetic n (%)	64 (9.4)	44 (13.6)	52 (16.0)	29 (16.9)	0.0028
Lipid lowering n (%)	109 (16.1)	61 (18.8)	58 (17.9)	34 (19.8)	0.149
Aspirin n (%)	137 (20.2)	79 (24.4)	89 (27.5)	55 (31.9)	<0.001

Values are reported as n (%), mean ± SD, or median (interquartile range). BMI=body mass index; BP=blood pressure; eGFR =estimated glomerular filtration rate; FBG=fasting blood glucose;

HDL= high-density lipoprotein; Hs-CRP = high-sensitivity C-reactive protein; LDL = low-density-lipoprotein; PBG= postprandial blood glucose; NT-proBNP = N-terminal pro-type B

natriuretic peptide.

Associations of Baseline hs-cTnT Levels With MACE and All-Cause Mortality

In a series of Cox proportional hazards models adjusting for age and gender (model 1) and further adjusting for traditional cardiovascular risk factors (model 2), higher hs-cTnT categories demonstrated a graded association with MACE. Only modest attenuation of the hazards was found with further adjustment for renal function (model 3). Although significant attenuation was discovered with additional adjustment for hs-CRP and NT-proBNP level (model 4), hs-cTnT in the third category (hazard ratio [HR], 2.31 [95% CI, 1.39-3.84]) and fourth category (HR, 3.27 [95% CI, 1.88-5.70]) remained independently associated with MACE in the fully adjusted models. Participants in hs-cTnT categories 3 and 4 also had a significantly higher risk of coronary events compared with participants with undetectable levels (HRs of 2.76 [95% CI, 1.44-5.31] and 4.50 [95% CI, 2.26 - 9.02], respectively, in model 4, Table2). However, associations of hs-cTnT levels with incident stroke were markedly attenuated and no longer significant after adjusting for NT-proBNP (model 4, Table2). Not only in the univariate Cox regression analysis but also in multivariate models, those participants in the highest hs-cTnT category were independently associated with the all-cause mortality risk (HR 2.07, [95% CI, 1.05-3.01]).

In an exploring research of hs-cTnT as a continuous variable after natural logarithm transformation, we disclosed a continuous association with MACE incident (per one-ln unit increment; HR, 1.67; 95% CI, 1.04–2.68; $P < 0.001$), with coronary events (HR, 1.68; 95% CI, 1.35–2.08; $P < 0.001$) and with all-cause death (HR, 1.50;

95% CI, 1.26–1.79; P=0.003) in the fully multivariate models including variables described in Table 2. The same, the relationship between hs-cTnT as a continuous variable and stroke risk were not presented in the final adjusted models (HR, 1.06; 95% CI, 0.87 – 1.32; P=0.17).

Table 2. Cox Proportional Hazards Models Analysis for Associations Between Baseline Hs-cTnT Levels and Outcomes

	Hazard Ratio (95% Confidence Interval)			
	Group 1 <3.00 ng/L	Group 2 3.0-6.21 ng/L	Group 3 6.22-<14 ng/L	Group 4 ≥14 ng/L
No.	679	324	324	172
MACE	n=25 (3.7%)	n=30 (9.3%)	n=59 (18.2%)	n=40 (23.3%)
Model 1	1[Reference]	1.65 (0.97-2.81)	2.65 (1.64-4.27)	4.20 (2.51-7.02)
Model 2	1[Reference]	1.52 (0.89-2.59)	2.41 (1.48-3.91)	3.82 (2.27-6.43)
Model 3	1[Reference]	1.52 (0.89-2.61)	2.38 (1.47-3.88)	3.79 (2.26-6.39)
Model 4	1[Reference]	1.68 (0.97-2.92)	2.31 (1.39-3.84)	3.27 (1.88-5.70)
Coronary event	n=14 (2.1%)	n=17 (5.3%)	n=41 (12.7%)	n=27 (15.7%)
Model 1	1[Reference]	1.69 (0.83-3.44)	3.39 (1.82-6.29)	5.23 (2.7-10.14)
Model 2	1[Reference]	1.61 (0.78-3.29)	3.25 (1.74-6.07)	5.5 (2.84-10.64)
Model 3	1[Reference]	1.57 (0.76-3.22)	3.09 (1.65-5.79)	5.14 (2.65-9.98)
Model 4	1[Reference]	1.42 (0.71-2.89)	2.76 (1.44-5.31)	4.50 (2.26-9.02)
Stroke event	n=11 (1.6%)	n=13 (4.0%)	n=20 (6.2%)	n=17 (9.9%)
Model 1	1[Reference]	1.59 (0.71-3.57)	1.94 (0.91-4.14)	3.84 (1.75-8.43)
Model 2	1[Reference]	1.47 (0.65-3.29)	1.77 (0.83-3.79)	3.19 (1.42-7.16)
Model 3	1[Reference]	1.47 (0.65-3.31)	1.70 (0.79-3.66)	3.16 (1.41-7.10)
Model 4	1[Reference]	1.03 (0.50-2.09)	1.13 (0.57-2.14)	1.27 (0.69-2.62)
All-cause mortality	n=8 (1.2%)	n=7 (2.2%)	n=16 (4.9%)	n=21 (12.2%)
Model 1	1[Reference]	1.13 (0.41-3.14)	1.99 (0.83-4.76)	6.14 (2.61-14.46)

Model 2	1[Reference]	1.13 (0.41-3.14)	1.78 (0.73-4.35)	4.87 (1.99-11.88)
Model 3	1[Reference]	1.14 (0.41-3.16)	1.79 (0.73-4.38)	4.87 (1.99-11.88)
Model 4	1[Reference]	1.01 (0.40-1.15)	1.09 (0.43-2.76)	2.07 (1.05-3.01)

Abbreviations: MACE, major adverse cardiovascular event.

Models are defined as follows: model 1=adjusted for age and gender; model 2=adjusted for model 1+ presence of hypertension or diabetes mellitus, smoking status (current vs not), systolic blood pressure, postprandial blood glucose, total cholesterol, high-density lipoprotein cholesterol, antihypertensive medication use, and antidiabetic medication use; model 3= adjusted for model 2+estimated glomerular filtration rate; model 4= adjusted for model 3+ high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide (both ln transformed).

Changes in hs-cTnT Concentration During Follow-up and

Subsequent Events

Table 3 represents the results of Cox regression analysis for subsequent events in relation to changes in hs-cTnT concentration as a continuous variable. Changes in hs-cTnT concentration were strongly associated with subsequent events except for stroke, even in multivariable analyses that additionally adjusted for baseline hs-cTnT levels. In the fully adjusted models, the HR for MACE for every unit increasing in hs-cTnT was 1.35 (95% CI: 1.08-1.68, $p=0.008$), as well as coronary event (HR: 1.44, 95% CI: 1.17-1.77, $p=0.001$). Likewise, an increase in hs-cTnT levels was not so remarkably associated with incident stroke (HR: 1.02, 95% CI: 0.64-2.19, $p=0.242$).

Table 3. Association of Changes in hs-cTnT Concentrations With Subsequent

Events

	Multivariable adjusted HR	95% CI	p Value
MACE	1.35	1.08-1.68	0.008
Coronary event	1.44	1.17-1.77	0.001

Stroke event	1.02	0.64-2.19	0.242
--------------	------	-----------	-------

Abbreviations: HR, hazard ratio; CI, confidence interval; MACE, major adverse cardiovascular event. Data are presented as hazard ratio and 95% confidence intervals for a 1-unit increase of changes in hs-cTnT on a log scale.

Multivariable adjusted model adjusted for the covariates listed in Table 2 Model 4 plus baseline hs-cTnT level.

Discussion

The main purpose of the current study was to evaluate the usefulness of high-sensitivity cardiac troponin T determination for prediction of major cardiovascular events and all-cause mortality in a community-based study of general population. Several valuable findings emerged from our study. First, we used the up-to-date generation of hs-cTnT assay, allowing us to reliably detect minimal subclinical myocardial injury in some of the general population over a wide age coverage, not restricted to morbid or high-risk individuals. Second, the baseline and kinetic changes of hs-cTnT were powerful and independent predictors of long term MACE and all-cause mortality. Finally, these risk prediction was persistent even after adjustment for traditional cardiovascular risk factors as well as adjustment for biomarkers of inflammation and cardiac wall strain.

Generally, cardiac troponins are the preferred biomarkers of myocardial necrosis, typically in the diagnosis of acute coronary syndromes, but the recently available hs-cTnT assay has allowed detection of much lower concentrations of circulating cTnT. More recent observations have showed that very low levels of circulating cTnT can be detectable in patients with stable coronary artery disease,[14-15] and even in the general population by this new assay.[16-17] The exact mechanisms of troponins

1
2
3
4 release in apparently healthy individuals are not well clarified, one possibility is the
5
6 existence of asymptomatic cardiac ischemia with minimal myocardial injury resulting
7
8 in troponins release without any symptoms.[18] Other mechanisms including
9
10 cardiomyocyte apoptosis,[19] physiological cell turnover,[20] or subclinical cardiac
11
12 structural or functional abnormalities.[21-22]
13
14

15
16 The independent association between circulating levels of hs-cTnT and the
17
18 incidence of adverse cardiovascular outcomes were previous reported in patients with
19
20 chronic HF and stable CHD, and we now extend the findings to a general population
21
22 of middle-aged to elderly. One important finding is the observation that the presence
23
24 of an elevated hs-cTnT level (in the highest category) was associated with adverse
25
26 outcomes regarding all-cause mortality and the MACE. However, the associations of
27
28 minimally detectable hs-cTnT (especially those below 6.2ng/L, in the second category)
29
30 with death or MACE were not present in comparison to the undetected group. It has
31
32 been proposed that such levels may be physiological, reflecting normal myocardial
33
34 cell turnover and apoptosis within the senescent heart tissue.[23] Further research is
35
36 required into which hs-cTnT threshold value may best be used in risk prediction.
37
38
39
40
41
42
43

44 While other biomarkers such as hs-CRP and NT-proBNP have been used to
45
46 identify apparently healthy individuals who are at increased CVD risk,[24-25] our
47
48 investigation indicates that hs-cTnT is also independent of these biomarkers. In this
49
50 cohort, although associations with death and cardiovascular events were significantly
51
52 attenuated after additional adjustment for levels of NT-proBNP, hs-cTnT remained
53
54 independently predictive for end points in the final model, suggesting that the two
55
56
57
58
59
60

1
2
3
4 biomarkers convey slightly different information in cardiac structural and functional
5
6 abnormalities. The HRs remained statistically significant after adjusting for traditional
7
8 cardiovascular risk factors and renal function, is also in agreement with data from
9
10 other studies.[8, 26] All these data indicate that very low levels of hs-cTnT may
11
12 identify subclinical myocardial injury and lead to cardiovascular events risk not fully
13
14 estimated by current risk assessment methods.
15
16
17
18

19 Our data also suggest that even minimal changes in low levels of hs-cTnT have
20
21 prognostic characteristic and can help to identify individuals at long-term risk for
22
23 adverse events. There seems to be a dose dependent relationship between increased
24
25 hs-cTnT and increased risk. Consistently with our results, Christopher et al,[27] have
26
27 reported that changes in cTnT concentrations determined with a highly sensitive assay
28
29 were significantly associated with incident HF and cardiovascular death in community
30
31 -based older adults. Also, in a prospective cohort of ambulatory older adults, a strong
32
33 increase in the risk of sudden cardiac death [28] and incident atrial fibrillation [29]
34
35 were associated with changes over time in hs-cTnT concentrations. Although these
36
37 changes may reflect normal physiological variation, their relation to future adverse
38
39 events regardless of baseline hs-cTnT levels indicates that they may really represent
40
41 dynamic changes in risk stratification.
42
43
44
45
46
47
48

49 In contrast to the strong associations with mortality and MACE, hs-cTnT was not
50
51 associated with stroke occurrence after adjustment for multiple variables. There are
52
53 several potential explanations for this finding. First, cardiac troponin specially reflects
54
55 myocardial necrosis or subclinical myocardial injury, some previous studies indicate
56
57
58
59
60

1
2
3
4 that structural heart abnormalities are more powerful determinants of myocardial
5
6 injury among participants in the general population than coronary atherosclerosis.
7
8 [30-31] Second, the Atherosclerosis Risk in Communities (ARIC) Study[32] showed
9
10 that elevated plasma hs-cTnT levels were related with increased risk of non-lacunar
11
12 ischemic strokes, and especially cardioembolic stroke, but not with hemorrhagic
13
14 stroke in the general population. Epidemiological data demonstrated that there was
15
16 difference in stroke subtypes between Chinese and western, intracerebral hemorrhage
17
18 (ICH) accounts for only 10-15% of strokes in most western populations,[33] whereas
19
20 up to 55% of strokes in the Chinese population are ICH.[34] Although analysis for
21
22 likely ischemic stroke as an endpoint had also been carried out (data not shown), the
23
24 number of ischemic cause was less than one half of all strokes, and it was impossible
25
26 to obtain an evident difference in the results.
27
28
29
30
31
32

33
34 Our study also has several limitations. First, cardiovascular treatment has changed
35
36 with time and it is possible that more prevalent use of medicines such as statins and
37
38 antiplatelet drugs could lower the predictive value of hs-cTnT. Second, we lack
39
40 echocardiographic and coronary artery imaging data and can, thus, not provide causal
41
42 explanations on the associations between hs-cTnT, cardiac abnormalities, and
43
44 outcomes. Third, the incidence rate of the adverse events is relatively low in this
45
46 cohort and hs-cTnT are detected in a considerable proportion, which limits its
47
48 potential for long-term predictive usefulness. So the predictive value of hs-cTnT need
49
50 to be further validated in other observational studies.
51
52
53
54
55

56 **Conclusion**

57
58
59
60

1
2
3
4 In this prospective cohort of community-dwelling population, we found both
5
6 baseline and change in cardiac troponin T which detected by a highly sensitive assay
7
8 were independently associated with adverse outcomes. It is suggested that hs-cTnT
9
10 may be an important biomarker in the prediction of mortality and cardiovascular
11
12 events in apparently healthy individuals. Further investigations therefore are
13
14 warranted to elucidate mechanisms for hs-cTnT release in these individuals and to test
15
16 whether active interventions can reduce the associated risk contributed by elevated
17
18 troponin levels.
19
20
21
22

23
24 **Contributorship statement:** The manuscript has been read and approved by all
25
26 of the authors. All authors contributed to the intellectual development of this paper.

27
28
29 Conceived and designed the experiments: Ping Ye. Performed the experiments:
30
31 Wenkai Xiao, Yuan Liu. Analyzed the data: Wenkai Xiao and Yongyi Bai. Wrote the
32
33 manuscript: Wenkai Xiao. Supervised data collection: Rui Cao, Hongmei Wu.
34
35

36
37 **Competing Interests:** The authors have declared that no competing interests
38
39 exist.
40

41
42 **Funding:** This study was supported by grants from the Key National Basic
43
44 Research Program of China (2012CB517503, 2013CB530804) and the Key Science
45
46 and Technology Foundation of China (2012ZX09303004-002) to P Ye.
47
48

49
50 **Data sharing statement:** The additional unpublished data from the study are
51
52 available. We can share the original data for this research article.
53

54
55 **Acknowledgements** We thank our colleagues at the Department of Laboratory
56
57 Medicine of the PLA General Hospital for their help with biochemical measurements.
58
59
60

We are also grateful to all study participants for their rigorous work.

References

1. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA* 2003;290:898-904.
2. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *JAMA* 2009;302:49-57.
3. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project. *Circulation* 2010;121:2388-97.
4. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. *Eur Heart J* 2010;31: 2197–204.
5. Bandstein N, Ljung R, Johansson M, et al. Undetectable High-Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction. *J Am Coll Cardiol* 2014;63:2569-78.
6. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med* 2008;358: 2107–16.
7. Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. *J Am Coll Cardiol* 2008;52:450–9.

- 1
2
3
4 8. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T
5
6 and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men.
7
8
9 *Am Heart J* 2013;166:541-8.
- 10
11 9. Masson S, Anand I, Favero C, et al. Serial Measurement of Cardiac Troponin T
12
13 Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. *Circulation*
14
15 2012;125:280-8.
- 16
17 10. Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T and
18
19 secondary events in outpatients with coronary heart disease from the Heart and Soul
20
21 Study. *JAMA Intern Med* 2013;173:763–9.
- 22
23 11. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-
24
25 sensitivity cardiac troponin T assay. *Clin Chem* 2010;56:254-261.
- 26
27 12. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating
28
29 equation for chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17:
30
31 2937-44.
- 32
33 13. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for
34
35 the 21st century: statement for healthcare professionals from the American
36
37 Heart Association/American Stroke Association. *Stroke* 2013;44:2064-89.
- 38
39 14. Oemrawsingh RM, Cheng JM, García-García HM, et al. High-sensitivity
40
41 Troponin T in relation to coronary plaque characteristics in patients with stable
42
43 coronary artery disease; results of the ATHEROREMO-IVUS study. *Atherosclerosis*
44
45 2016;247:135-41.
- 46
47 15. Giannitsis E, Spanuth E, Horsch A, et al. High-sensitivity cardiac troponin T and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery
5
6 disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC)
7
8 study. *Clin Chem Lab Med* 2013;51:2019-28.
9

10
11 16. Rubin J, Matsushita K, Lazo M, et al. Determinants of minimal elevation
12
13 in high-sensitivity cardiac troponin T in the general population. *Clin Biochem* 2016;
14
15 49:657-62.
16
17

18
19 17. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a
20
21 highly sensitive assay predicts coronary heart disease, heart failure, and mortality in
22
23 the Atherosclerosis Risk in Communities Study. *Circulation* 2011;123:1367-76.
24
25

26
27 18. Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid
28
29 atrial pacing causes troponin T release detectable by a highly sensitive assay: insights
30
31 from a coronary sinus sampling study. *J Am Coll Cardiol* 2011;57:2398-405.
32
33

34
35 19. White HD. Pathobiology of troponin elevations: do elevations occur with
36
37 myocardial ischemia as well as necrosis? *J Am Coll Cardiol* 2011;57:2406-8.
38

39
40 20. Røsjø H, Andreassen J, Edvardsen T, et al. Prognostic usefulness of circulating
41
42 high-sensitivity troponin T in aortic stenosis and relation to echocardiographic
43
44 indexes of cardiac function and anatomy. *Am J Cardiol* 2011;108:88-91.
45

46
47 21. Kawasaki T, Sakai C, Harimoto K, et al. Usefulness of High-Sensitivity Cardiac
48
49 Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in
50
51 Patients With Hypertrophic Cardiomyopathy. *Am J Cardiol* 2013;112:867-72.
52
53

54
55 22. Jenab Y, Pourjafari M, Darabi F, et al. Prevalence and determinants of elevated
56
57 high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. *Journal of*
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cardiology 2014;63:140-4.

23. Sze J, Mooney J, Barzi F, et al. Cardiac Troponin and its Relationship to Cardiovascular Outcomes in Community Populations – A Systematic Review and Meta-analysis. *Heart Lung Circ* 2016;25:217-28.

24. Schnell-Inderst P, Schwarzer R, Göhler A, et al. Prognostic value, clinical effectiveness, and cost-effectiveness of high - sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. *Int J Technol Assess Health Care* 2010; 26:30-9.

25. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of N- terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2015; 170:1170-83.

26. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro –B type natriuretic peptide are associated with cardiovascular events despite the cross- sectional association with albuminuria and glomerular filtration rate. *Eur Heart J* 2012; 33:2272-81.


27. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA* 2010;304:2494-502.

28. Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. *J Am Coll Cardiol* 2013;62:2112-20.

- 1
2
3
4 29. Hussein AA, Bartz TM, Gottdiener JS, et al. Serial measures of cardiac troponin
5
6 T levels by a highly sensitive assay and incident atrial fibrillation in a prospective
7
8 cohort of ambulatory older adults. *Heart Rhythm* 2015;12:879-85.
9
10
11 30. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected
12
13 with a highly sensitive assay and cardiac structure and mortality risk in the general
14
15 population. *JAMA* 2010;304:2503-12.
16
17
18 31. de Lemos JA, deFilippi CR. Prevalence and significance of detectable troponins as
19
20 measured by highly sensitive assays in the general population. *Coronary Artery*
21
22 *Disease* 2013;24:705-9.
23
24
25 32. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-Terminal Pro-B-Type
26
27 Natriuretic Peptide, and Incidence of Stroke. The Atherosclerosis Risk in
28
29 Communities Study. *Stroke* 2013; 44:961-7.
30
31
32 33. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke
33
34 statistics-2009 update: a report from the American Heart Association Statistics
35
36 Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:480-6.
37
38
39 34. Yang QD, Niu Q, Zhou YH, et al. Incidence of cerebral hemorrhage in the
40
41 Changsha community. A prospective study from 1986 to 2000. *Cerebrovasc Dis.*
42
43
44 2004;17:303-13.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A Major adverse cardiovascular events




171x140mm (96 x 96 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

B Coronary event




159x128mm (96 x 96 DPI)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

C Stroke




125x129mm (96 x 96 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

D All-cause mortality



159x128mm (96 x 96 DPI)

For peer review only

BMJ Open

Association of High-Sensitivity Cardiac Troponin T with Mortality and Cardiovascular Events in a Community-Based Prospective Study in Beijing

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013431.R1
Article Type:	Research
Date Submitted by the Author:	06-Jan-2017
Complete List of Authors:	Xiao, Wenkai Cao, Ruihua; Chinese PLA General Hospital, Geriatric Cardiology Liu, Yuan; Chinese PLA General Hospital, Geriatric Cardiology Bai, Yongyi; Chinese PLA General Hospital, Geriatric Cardiology Wu, Hongmei; Chinese PLA General Hospital, Geriatric Cardiology Ye, Ping; Chinese PLA General Hospital, Geriatric Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology
Keywords:	Biomarkers, Cardiac Epidemiology < CARDIOLOGY, risk assessment, prognosis

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Association of High-Sensitivity Cardiac Troponin T with Mortality and Cardiovascular Events in a Community-Based Prospective Study in Beijing

Wenkai Xiao, Ruihua Cao, Yuan Liu, Yongyi Bai, Hongmei Wu, Ping Ye *

Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, 100853, China

Correspondence to Ping Ye, Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, 100853, China

Tel:+86-10-66876369; Fax:+86-10-66876349; E-mail: yeping301@sina.com

Keywords: Biomarkers; High-sensitivity cardiac troponin T; cardiovascular diseases; prognosis; risk assessment.

Word count: 5860

Abstract

Objective: The prognostic value of cardiac troponins in apparently healthy populations is not well established. The aim of this study is to investigate the prognostic properties of high-sensitivity cardiac troponin T (hs-cTnT) for long-term adverse outcomes.

Setting: A community-dwelling prospective survey of residents from two communities in Beijing.

Participants: From September 2007 to January 2009, 1680 participants were initially enrolled, of whom 1,499 (870 females, mean age 61.4 years) completed the survey and were followed up for a median of 4.8 years (interquartile range, 4.5-5.2).

Outcome measures: primary outcomes were the occurrence of all-cause mortality and major cardiovascular events.

Results: In total, 820 individuals (54.7%) had detectable hs-cTnT levels. During follow-up, 52 participants (3.5%) died, 154 (10.3%) had major cardiovascular events, and 99 (6.6%) experienced new-onset coronary events. Compared with participants with undetectable levels, those with hs-cTnT levels in the highest category (≥ 14 ng/L) had significantly increased risk for all-cause mortality (adjusted hazard ratio [aHR] = 2.07; 95% confidence interval [CI], 1.05 to 3.01), major cardiovascular events (aHR = 3.27; 95% CI, 1.88 to 5.70), and coronary events (aHR = 4.50; 95% CI, 2.26 to 9.02) but not for stroke incident (aHR = 1.27; 95% CI, 0.69 to 2.62) in covariate-adjusted analyses. Also the significant associations were presented when hs-cTnT levels were modeled as a continuous variable and when analyzing changes over time in the

1
2
3
4 hs-cTnT levels with adverse outcomes. Addition of troponin T levels to clinical
5
6 variables led to significant increases in risk prediction with significant improvement
7
8 of the c-statistic (P=0.003 or lower).
9

10
11 **Conclusions:** In this cohort of individuals from a community-based population,
12
13 cardiac troponin T measured with a highly sensitive assay was associated with
14
15 subsequent risk for all-cause mortality and major cardiovascular events, which might
16
17 support screening for at risk individuals.
18
19

20 21 22 23 24 25 26 **Strengths and limitations of this study** 27

- 28
29 ■ Evaluating the prognostic properties of both baseline and change in hs-cTnT for
30
31 long-term adverse outcomes in a large community-dwelling study.
32
- 33
34 ■ Reliably detected minimal subclinical myocardial injury in an apparently healthy
35
36 population over a wide age range.
37
- 38
39 ■ Absence of echocardiographic and coronary artery imaging data and thus, could
40
41 not provide causal explanations on the associations between hs-cTnT and
42
43 outcomes.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Cardiovascular disease (CVD) is still the primary cause of morbidity and mortality globally. There is concordant evidence that prevention is the key to lessening the CVD burden, but risk prediction of adverse cardiovascular events in low- to intermediate-risk individuals is a big challenge.¹ This subpopulation are at risk for developing CVD but are not identified early by current risk-factor screening methods.²⁻³ Circulating biomarkers can be an important supplemental screening tool, and one of the most interesting biomarkers in this context is troponins. Cardiac troponin T (cTnT) is a regulatory protein expressed by cardiac myocytes and released in the setting of myocardial injury.⁴⁻⁵ A sensitive and specific marker of cardiomyocytes damage, cTnT is typically used clinically in the earlier exclusion or confirmation of the diagnosis of acute myocardial infarction (AMI).

However, cTnT levels can also be elevated and clinically meaningful in the absence of myocardial ischemia. Detectable levels of cTnT can also be useful for detecting subclinical CVD and assessing CVD risk in the general population; however, cTnT is only detectable in a small percentage of the general population using standard assays,⁶⁻⁷ which limit the utility for clinical applications. Recently, a highly sensitive cTnT (Hs-cTnT) assay has been developed, which can detect 10-fold lower concentrations than the standard fourth-generation assay. The introduction of this new assay has enabled detection of very low levels of circulating cTnT, even in some asymptomatic general population.⁸

cTnT levels below the detection limit of standard assays were independently

1
2
3 associated with adverse cardiovascular events in patients with heart failure (HF) ⁹ or
4 stable coronary heart disease (CHD). ¹⁰ But the clinical significance of detectable
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

associated with adverse cardiovascular events in patients with heart failure (HF) ⁹ or stable coronary heart disease (CHD). ¹⁰ But the clinical significance of detectable cTnT with the use of the new assay in the apparently healthy population is not well established. The main objective of this study was to investigate the prognostic value of minimally detectable hs-cTnT levels in predicting adverse clinical events in a population of community-based subjects.

Methods

Study population

This is a prospective observational study of people living in the Pingguoyuan area of the Shijingshan district, a metropolitan area of Beijing, China. Initially, between September 2007 and January 2009, all permanent residents of Han origin aged 45 years or older (range 45~91 years) from two communities were invited to participate in a health survey that focused on identifying CVD risk factors. 31 subjects with bedridden status, mental illness, and severe systemic diseases were excluded from the enrollment. Then 1,832 participants were included and provided questionnaires. Of those, 152 participants with overt CVD (defined as a composite of CHD [myocardial infarction, angina pectoris, or coronary insufficiency], cerebrovascular disease [stroke or transient ischemic attack], congestive HF, or peripheral vascular disease) were excluded. Thus, adequate baseline measurements and cardiac biomarkers were obtained in 1680 participants. After the initial evaluation, recruited subjects were contacted every 2 years for follow-up, and the last follow-up visits were conducted through September 30, 2013. The median follow-up was 4.8

1
2
3
4 (interquartile range 4.5-5.2) years. In our investigation, 181 participants were lost to
5
6 follow-up (supplementary Table 1 shows the clinical characteristics) and were
7
8 excluded from the study, complete data were acquired from 1499 participants (return
9
10 rate, 89.2%). All participants provided written informed consent at time of enrollment,
11
12 and the study was approved by the Ethics Committee of the Chinese People's
13
14 Liberation Army (PLA) General Hospital.
15
16

17 18 19 **Data collection**

20
21 Baseline characteristics for this analysis were collected using self-reported
22
23 standardized questionnaires that included demographics, life-style information,
24
25 medical history, and medication use. Anthropometrical measurements were obtained
26
27 by trained medical doctors, and the body mass index (BMI) was derived from height
28
29 and weight measured with participants wearing light clothing and no shoes. Blood
30
31 pressures were measured two times on the right arm after 5 minutes of rest in a sitting
32
33 position, the mean of 2 readings were used for further analysis. Participants were
34
35 followed up for clinical outcomes by interview. Outcome measures were occurrences
36
37 of all-cause mortality and major adverse cardiovascular event (MACE), new events
38
39 were validated by obtaining medical records and adjudicated by 2 independent and
40
41 blinded reviewers. In our analyses, survival time was defined as the period from the
42
43 date of baseline blood sample collection to the date of the first adverse event or end of
44
45 follow-up.
46
47
48
49
50
51
52

53 54 **Biomarker Assays**

55
56 After at least 12 hours of overnight fasting, baseline blood samples were
57
58
59
60

1
2
3
4 collected from participants between 8 AM and 10 AM at enrollment. Follow-up
5
6 measurements were performed on blood samples collected 4 to 5 years later. Serum
7
8 aliquots were frozen at -80°C until analysis in a central laboratory were performed.
9
10 Concentrations of blood glucose (fasting and 2 hours after an oral glucose tolerance),
11
12 total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol
13
14 (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid and serum
15
16 creatinine levels were measured by routine laboratory analysis.
17
18
19

20
21 Hs-cTnT were measured by an electrochemiluminescence immunoassay method
22
23 using an Elecsys Troponin T highly sensitive assay (Roche Diagnostics GmbH,
24
25 Mannheim, Germany) on the Modular Analytics E170 autoanalyzer (Roche
26
27 Diagnostics). The lower detection limit of the novel assay was 3 ng/L and a reported
28
29 99th percentile value in apparently healthy individuals was 14 ng/L.¹¹ N-terminal
30
31 pro-B-type natriuretic peptide (NT-proBNP) concentrations were determined using an
32
33 electrochemiluminescence immunoassay (Roche Diagnostics GmbH) on the Roche
34
35 analyzer. Levels of high-sensitivity C-reactive protein (hs-CRP) were measured with
36
37 the use of immunoturbidimetric assay (Siemens Healthcare Diagnostics, IN, USA) on
38
39 a Dimension RxL Max analyzer (Siemens Healthcare Diagnostics).
40
41
42
43
44
45

46 Estimated glomerular filtration rate (eGFR) was calculated using the Chinese
47
48 modifying Modification of Diet in Renal Disease (C-MDRD) equation, details of the
49
50 computing equation have been published elsewhere.¹²
51
52

53 54 **Definition of end points**

55
56 For outcomes, we used the incidence of mortality and CVD morbidity after the
57
58
59
60

1
2
3
4 baseline screening. All-cause mortality was determined by review of death certificates.
5
6 The definition of MACE comprised nonfatal MI, ischaemic heart disease (identified
7
8 by coronary artery imaging or receiving coronary revascularization), stroke
9
10 (ischaemic or haemorrhagic), and cardiovascular mortality. Major coronary events
11
12 were defined as nonfatal MI, ischaemic heart disease, and CHD death. Stroke was
13
14 characterized as a neurological deficit attributed to an acute focal injury of the central
15
16 nervous system by a vascular cause, including cerebral infarction, intracerebral
17
18 hemorrhage, and subarachnoid hemorrhage.¹³ Cardiovascular mortality was defined
19
20 as mortality related to atherosclerotic heart disease (fatal MI and definite fatal CHD),
21
22 mortality following cerebrovascular disease, or mortality from other atherosclerotic
23
24 and CVD including HF. Nonfatal MI was defined by the American Heart Association
25
26 diagnostic criteria.¹⁴
27
28
29
30
31
32

33 **Statistical analysis**

34
35
36 Continuous variables are reported as mean \pm standard deviation (SD) or median
37
38 (interquartile range) and categorical variables as count and percentages. We modeled
39
40 hs-cTnT as both a categorical and a continuous variable. For the analyses of hs-cTnT
41
42 as a categorical variable, we divided participants into 4 categories: those with
43
44 undetectable hs-cTnT were placed in the first category as the reference group; those
45
46 with hs-cTnT levels greater than or equal to the previously reported 99th percentile
47
48 value (14 ng/L)[11] were placed in the fourth category, and those with levels between
49
50 3 and 14 ng/L were divided into two groups for categories 2 and 3 based on the
51
52 median value of hs-cTnT. Demographic and clinical variables were compared across
53
54
55
56
57
58
59
60

1
2
3
4 hs-cTnT categories using the one-way analysis of variance tests for continuous
5
6 measures, Cuzik's nonparametric trend test for nonnormally distributed variables, and
7
8 chi-squared tests were performed for categorical variables.
9

10
11 Cumulative incidence of MACE and all-cause mortality for each category of
12
13 hs-cTnT concentration was evaluated using the Kaplan-Meier method and compared
14
15 with the log-rank test. Multivariable Cox proportional hazards regression models
16
17 were used to analyze associations of hs-cTnT categories with outcomes with category
18
19 1 used as the referent. The models were incrementally adjusting for demographics,
20
21 traditional cardiovascular risk factors, renal function and other biomarkers (Hs-CRP
22
23 and NT-proBNP) levels. We also carried an exploratory analysis in which we regarded
24
25 cTnT as a continuous variable and assessed the relationship between natural logarithm
26
27 transformed hs-cTnT values and end points. In this analysis, values of cTnT that were
28
29 below the lower limit of detection were assigned to 1.5 ng/L (i.e., one-half of the
30
31 lower limit of detection).
32
33
34
35
36
37
38

39 In view of the markedly skewed distribution of cTnT, changes in concentrations
40
41 over time were calculated as the difference between the natural logarithm of the
42
43 concentrations at follow-up and at baseline. The association between changes in
44
45 hs-cTnT levels and outcomes were also evaluated in Cox proportional hazards models.
46
47 The change in hs-cTnT levels was entered as a continuous variable and adjusted for
48
49 baseline concentration of hs-cTnT and for the relevant variables described previously
50
51 in multivariable models.
52
53
54

55
56 The discriminative capacity of a model with and without cTnT was estimated as
57
58
59
60

1
2
3
4 C-statistics. The area under the receiver operating characteristic curve summarized the
5
6 diagnostic discrimination. All data were analyzed using the SPSS statistical package
7
8 software (version 17.0). A two-sided value of $P < 0.05$ was considered statistically
9
10 significant.

11 12 13 **Results**

14 15 **Participant Characteristics**

16
17 For the present analyses, 1499 participants were included. The mean (\pm SD)
18
19 age of participants at enrollment was 61.4 ± 11.4 years and 58.0% were women. cTnT
20
21 was detectable at baseline in 820 individuals (54.7%) and was equal to or higher than
22
23 14 ng/L in 172 participants (11.5%), the detectable cTnT levels ranged from 3 to
24
25 176.4 ng/L. Table 1 shows baseline characteristics by hs-cTnT categories. Compared
26
27 with those with lower cTnT levels, individuals with higher levels were older, were
28
29 more likely to be male, more frequently hypertensive and diabetic, had lower eGFR
30
31 and HDL-C levels, and had higher uric acid, NT-proBNP levels. In cardiovascular
32
33 drug use, use of antihypertensive, antidiabetic, and aspirin varied across levels of
34
35 hs-cTnT.
36
37
38
39
40
41
42

43 44 **Outcomes by Baseline Hs-cTnT Level**

45
46 Over a median follow-up period of 4.8 years (interquartile range, 4.5-5.2), 154
47
48 participants experienced new-onset MACE (including 99 coronary events and 61
49
50 strokes, some participants had more than one event) and 52 deaths occurred from any
51
52 cause. The cumulative incidence of MACE and all-cause mortality by hs-cTnT
53
54 categories are shown in Figure 1. As demonstrated by the Kaplan-Meier survival
55
56
57
58
59
60

1
2
3 analysis, there was a graded increase in the probability of adverse clinical events
4
5
6 across the categories. The unadjusted incidence rate for MACE ranged from 3.7% in
7
8
9 those participants with undetectable hs-cTnT levels to 23.3% for subjects in the
10
11 highest category (P<0.001, log-rank test). Similar trends were discovered for coronary
12
13 events, stroke, and all-cause mortality, with a particularly high risk was found for
14
15 those in the highest category.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table1. Characteristics of Study Population by Baseline high-sensitivity troponin T Levels

Characteristics	Hs-cTNT Group (ng/L)				P value for Trend
	Group 1 <3.00 (n = 679)	Group 2 3.00-6.21 (n=324)	Group 3 6.22-<14 (n= 324)	Group4 ≥14 (n = 172)	
Demographic					
Age (years)	58.6±10.3	63.1±10.7	64.2±12.4	61.8±11.5	<0.001
Male Sex n (%)	202 (29.7)	163 (50.3)	170 (52.5)	94 (54.7)	<0.001
BMI (kg/m ²)	25.5±3.5	25.7±3.2	25.6±3.3	25.8±3.5	0.498
Medical history					
Hypertension n (%)	258 (38.0)	159 (49.1)	176 (54.3)	97 (56.4)	<0.001
Diabetes mellitus n (%)	99 (14.6)	72 (22.2)	76 (23.5)	45 (26.2)	<0.001
Current smoking n (%)	85 (12.5)	69 (21.3)	62 (19.1)	31(18.0)	0.003
Systolic BP (mm Hg)	131.5±16.5	132.7±17.3	132.8±17.2	133.2±17.1	0.041
Diastolic BP (mm Hg)	77.1±9.7	77.3±10.0	76.4±10.5	76.1±11.1	0.372
Laboratory values					
FBG (mmol/L)	5.3±1.4	5.3±1.5	5.5±1.7	5.8±1.9	0.076
PBG (mmol/L)	7.5±3.7	7.1±3.2	8.1±4.3	8.9±4.4	<0.001

Total cholesterol (mmol/L)	5.1±0.9	5.1±0.9	5.1±0.9	5.0±0.9	0.464
Triglycerides (mmol/L)	1.8±1.1	1.7±1.1	1.7±1.0	2.0±1.4	0.04
LDL cholesterol (mmol/L)	3.0±0.7	2.9±0.7	3.0±0.7	3.0±0.7	0.136
HDL cholesterol (mmol/L)	1.4±0.4	1.4±0.3	1.3±0.4	1.3±0.4	0.001
Uric acid (µmol/L)	279.0±68.2	295.9±73.3	301.2±75.4	309.5±76.2	<0.001
eGFR (mL/min/1.73m ²)	90.1±14.5	88.7±13.4	87.5±15.2	84.7±16.5	0.001
NT-proBNP (pg/mL)	37.2 (17.9, 75.3)	38.9 (17.9, 74.4)	46.6 (22.3, 90.1)	49.3 (17.1, 112)	0.003
Hs-CRP (mg/L)	2.4 (1.3, 3.4)	2.3 (1.4, 3.4)	2.2 (1.5, 3.5)	2.4 (1.6, 3.6)	0.383
Medication use					
Antihypertensives n (%)	187 (27.5)	122 (37.7)	139 (42.9)	80 (46.5)	<0.001
Antidiabetic n (%)	64 (9.4)	44 (13.6)	52 (16.0)	29 (16.9)	0.0028
Lipid lowering n (%)	109 (16.1)	61 (18.8)	58 (17.9)	34 (19.8)	0.149
Aspirin n (%)	137 (20.2)	79 (24.4)	89 (27.5)	55 (31.9)	<0.001

Values are reported as n (%), mean ± SD, or median (interquartile range). BMI=body mass index; BP=blood pressure; eGFR =estimated glomerular filtration rate; FBG=fasting blood glucose;

HDL= high-density lipoprotein; Hs-CRP = high-sensitivity C-reactive protein; LDL = low-density-lipoprotein; PBG= postprandial blood glucose; NT-proBNP = N-terminal pro-type B

natriuretic peptide.

Associations of Baseline hs-cTnT Levels With MACE and All-Cause Mortality

In a series of Cox proportional hazards models adjusting for age and gender (model 1) and further adjusting for traditional cardiovascular risk factors (model 2), higher hs-cTnT categories demonstrated a graded association with MACE. Only modest attenuation of the hazards was found with further adjustment for renal function (model 3). Although significant attenuation was discovered with additional adjustment for hs-CRP and NT-proBNP level (model 4), hs-cTnT levels in the third category (hazard ratio [HR], 2.31 [95% CI, 1.39-3.84]) and fourth category (HR, 3.27 [95% CI, 1.88-5.70]) remained independently associated with MACE in the fully adjusted models. Participants in hs-cTnT categories 3 and 4 also had a significantly higher risk of coronary events compared with participants with undetectable levels (HRs of 2.76 [95% CI, 1.44-5.31] and 4.50 [95% CI, 2.26 - 9.02], respectively, in model 4, Table2). However, associations of hs-cTnT levels with stroke incidents were markedly attenuated and no longer significant after adjusting for NT-proBNP (model 4, Table2). Not only in the univariate Cox regression analysis but also in multivariate models, membership in the highest hs-cTnT category was independently associated with the all-cause mortality risk (HR 2.07, [95% CI, 1.05-3.01]).

In an exploratory research of hs-cTnT as a continuous variable after natural logarithm transformation, we found a continuous association with MACE incident (per one-ln unit increment; HR, 1.67; 95% CI, 1.04–2.68; $P < 0.001$), with coronary events (HR, 1.68; 95% CI, 1.35–2.08; $P < 0.001$) and with all-cause mortality (HR,

1.50; 95% CI, 1.26–1.79; P=0.003) in the fully multivariate models including variables described in Table 2. The association between cTnT as a continuous variable and stroke risk was not found in the final adjusted models (HR, 1.06; 95% CI, 0.87 – 1.32; P=0.17).

Table 2. Cox Proportional Hazards Models Analysis for Associations Between Baseline Hs-cTnT Levels and Outcomes

	Hazard Ratio (95% Confidence Interval)			
	Group 1 <3.00 ng/L	Group 2 3.0-6.21 ng/L	Group 3 6.22-<14 ng/L	Group 4 ≥14 ng/L
No.	679	324	324	172
MACE	n=25 (3.7%)	n=30 (9.3%)	n=59 (18.2%)	n=40 (23.3%)
Model 1	1[Reference]	1.65 (0.97-2.81)	2.65 (1.64-4.27)	4.20 (2.51-7.02)
Model 2	1[Reference]	1.52 (0.89-2.59)	2.41 (1.48-3.91)	3.82 (2.27-6.43)
Model 3	1[Reference]	1.52 (0.89-2.61)	2.38 (1.47-3.88)	3.79 (2.26-6.39)
Model 4	1[Reference]	1.68 (0.97-2.92)	2.31 (1.39-3.84)	3.27 (1.88-5.70)
Coronary event	n=14 (2.1%)	n=17 (5.3%)	n=41 (12.7%)	n=27 (15.7%)
Model 1	1[Reference]	1.69 (0.83-3.44)	3.39 (1.82-6.29)	5.23 (2.7-10.14)
Model 2	1[Reference]	1.61 (0.78-3.29)	3.25 (1.74-6.07)	5.5 (2.84-10.64)
Model 3	1[Reference]	1.57 (0.76-3.22)	3.09 (1.65-5.79)	5.14 (2.65-9.98)
Model 4	1[Reference]	1.42 (0.71-2.89)	2.76 (1.44-5.31)	4.50 (2.26-9.02)
Stroke event	n=11 (1.6%)	n=13 (4.0%)	n=20 (6.2%)	n=17 (9.9%)
Model 1	1[Reference]	1.59 (0.71-3.57)	1.94 (0.91-4.14)	3.84 (1.75-8.43)
Model 2	1[Reference]	1.47 (0.65-3.29)	1.77 (0.83-3.79)	3.19 (1.42-7.16)
Model 3	1[Reference]	1.47 (0.65-3.31)	1.70 (0.79-3.66)	3.16 (1.41-7.10)
Model 4	1[Reference]	1.03 (0.50-2.09)	1.13 (0.57-2.14)	1.27 (0.69-2.62)
All-cause mortality	n=8 (1.2%)	n=7 (2.2%)	n=16 (4.9%)	n=21 (12.2%)
Model 1	1[Reference]	1.13 (0.41-3.14)	1.99 (0.83-4.76)	6.14 (2.61-14.46)

Model 2	1[Reference]	1.13 (0.41-3.14)	1.78 (0.73-4.35)	4.87 (1.99-11.88)
Model 3	1[Reference]	1.14 (0.41-3.16)	1.79 (0.73-4.38)	4.87 (1.99-11.88)
Model 4	1[Reference]	1.01 (0.40-1.15)	1.09 (0.43-2.76)	2.07 (1.05-3.01)

Abbreviations: MACE, major adverse cardiovascular event.

Models are defined as follows: model 1=adjusted for age and gender; model 2=adjusted for model 1+ presence of hypertension or diabetes mellitus, smoking status (current vs not), systolic blood pressure, postprandial blood glucose, total cholesterol, high-density lipoprotein cholesterol, antihypertensive medication use, and antidiabetic medication use; model 3= adjusted for model 2+estimated glomerular filtration rate; model 4= adjusted for model 3+ high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide (both ln transformed).

Changes in hs-cTnT Concentration During Follow-up and Subsequent Events

Table 3 presents the results of Cox regression analysis for subsequent events in relation to changes in hs-cTnT concentration as a continuous variable. Changes in hs-cTnT concentration were strongly associated with subsequent events except for stroke, even in multivariable analyses that additionally adjusted for baseline hs-cTnT levels. In the fully adjusted models, the HR for MACE for every unit increasing in hs-cTnT concentration was 1.35 (95% CI: 1.08-1.68, $p=0.008$), as well as coronary event (HR: 1.44, 95% CI: 1.17-1.77, $p=0.001$). Likewise, an increase in hs-cTnT concentration was not so remarkably associated with incident stroke (HR: 1.02, 95% CI: 0.64-2.19, $p=0.242$).

Table 3. Association of Changes in hs-cTnT Concentrations With Subsequent Events

	Multivariable adjusted HR	95% CI	p Value
MACE	1.35	1.08-1.68	0.008

Coronary event	1.44	1.17-1.77	0.001
Stroke event	1.02	0.64-2.19	0.242

Abbreviations: HR, hazard ratio; CI, confidence interval; MACE, major adverse cardiovascular event. Data are presented as hazard ratio and 95% confidence intervals for a 1-unit increase of changes in hs-cTnT on a log scale.

Multivariable adjusted model adjusted for the covariates listed in Table 2 Model 4 plus baseline hs-cTnT level.

Hs-cTnT and Risk Prediction

Hs-cTnT provided incremental prognostic information regarding the three endpoints when added to a model based on established risk indicators (Table 4). The addition of hs-cTnT increased the c-statistic from 0.671 to 0.698 (P=0.003) for the prediction of all-cause mortality and improved prediction of MACE from 0.702 to 0.734 (P<0.001).

Table 4. Discrimination for adverse outcomes with the addition of hs-cTnT to clinical risk factor model.

Endpoint	c-statistic (95%CI)		p Value
	Clinical Model	Clinical Model + hs-cTnT	
All-cause mortality	0.671 (0.646-0.704)	0.698 (0.680-0.725)	P=0.003
MACE	0.702 (0.680-0.726)	0.734 (0.714-0.758)	<0.001
Coronary event	0.713 (0.701-0.735)	0.749 (0.729-0.768)	<0.001
Stroke event	0.683 (0.665-0.709)	0.697 (0.674-0.729)	P=0.09

Clinical risk factor model include age, gender, body mass index, current smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate.

Discussion

The main purpose of the current study was to evaluate the usefulness of high-sensitivity cardiac troponin T measurement for prediction of major cardiovascular events and all-cause mortality in a community-based study of general population. Several valuable findings emerged from our study. First, we used the up-to-date generation of cTnT assay, allowing us to reliably detect minimal subclinical myocardial injury in some individuals of a general population covering a wide age range, without restricting the study to morbid or high-risk individuals. Second, the baseline and kinetic changes of hs-cTnT concentration were powerful and independent predictors of long term MACE and all-cause mortality. Finally, these risk predictions were persistent even after adjustment for traditional cardiovascular risk factors as well as adjustment for biomarkers of inflammation and cardiac wall strain.

Cardiac troponins are generally the preferred biomarkers of myocardial necrosis, typically in the diagnosis of acute coronary syndromes, but the recently available hs-cTnT assay has allowed detection of much lower concentrations of circulating cTnT. More recent observations have showed that with this new assay, very low levels of circulating cTnT can be detectable and can provide information about the coronary plaque characteristics and mortality in patients with stable CHD;¹⁵⁻¹⁶ and that very low levels of circulating cTnT can even be detected in the general population.¹⁷⁻¹⁸ The exact mechanisms of troponins release in apparently healthy individuals are not well clarified. One possibility is the existence of asymptomatic cardiac ischemia with minimal myocardial injury resulting in troponins release

1
2
3 without any symptoms.¹⁹ Other mechanisms include cardiomyocyte apoptosis,²⁰
4
5 physiological cell turnover,²¹ or subclinical cardiac structural or functional
6
7 abnormalities.²²⁻²³
8
9

10
11 More recently, although the prognostic implications of hs-cTnT assays among
12
13 apparently healthy individuals have been explored in three large cohort studies,^{18, 24-25}
14
15 all the studies are of middle-aged to elderly general populations from western
16
17 countries. Now our study extends the findings to Asians and demonstrates the
18
19 significance of hs-cTnT assay in risk assessment. To the best of our knowledge, this is
20
21 the first study to evaluate the potential utility of hs-cTnT assay in a Chinese
22
23 population. One important finding is the observation that the presence of an elevated
24
25 hs-cTnT level (in the highest category) was associated with adverse outcomes
26
27 regarding all-cause mortality and MACE. However, the associations of minimally
28
29 detectable hs-cTnT levels (especially those below 6.2ng/L, in the second category)
30
31 with death or MACE were not present in comparison to the undetected group. It has
32
33 been proposed that such levels may be physiological, reflecting normal myocardial
34
35 cell turnover and apoptosis within the senescent heart tissue,²⁶ or cortisol response to
36
37 mental stress in healthy adults.²⁷ Further research is required into which hs-cTnT
38
39 threshold value may best be used in risk prediction.
40
41
42
43
44
45
46
47

48
49 While other biomarkers such as hs-CRP and NT-proBNP have been used to
50
51 identify apparently healthy individuals who are at increased CVD risk,²⁸⁻²⁹ our
52
53 investigation indicates that hs-cTnT is also independent of these biomarkers. In this
54
55 cohort, although associations with death and cardiovascular events were significantly
56
57
58
59
60

1
2
3
4 attenuated after additional adjustment for levels of NT-proBNP, hs-cTnT remained
5
6 independently predictive of end points in the final model, suggesting that the two
7
8 biomarkers convey slightly different information for cardiac structural and functional
9
10 abnormalities. The hazard ratios remained statistically significant after adjusting for
11
12 traditional cardiovascular risk factors and renal function, consistent with results from
13
14 other studies.^{8,30} All these data indicate that very low levels of cTnT may identify
15
16 subclinical myocardial injury and lead to cardiovascular events risk not fully
17
18 estimated by current risk assessment methods. Also, associations of hs-cTnT level
19
20 with all-cause mortality and MACE were consistent in stratification analysis defined
21
22 by sex.
23
24
25
26
27

28
29 Our data also suggest that even minimal changes in low levels of cTnT have
30
31 prognostic characteristics and can help to identify individuals at long-term risk for
32
33 adverse events. There seems to be a dose-dependent relationship between increased
34
35 hs-cTnT and increased risk. Consistently with our results, DeFilippi et al,²⁴ have
36
37 reported that changes in cTnT concentrations determined with a highly sensitive assay
38
39 were significantly associated with incident HF and cardiovascular death in community
40
41 -based older adults. Also, in a prospective cohort of ambulatory older adults, a strong
42
43 increase in the risk of sudden cardiac death³¹ and incident atrial fibrillation³² was
44
45 associated with changes over time in hs-cTnT concentrations. Although these changes
46
47 may reflect normal physiological variation, their relation to future adverse events
48
49 regardless of baseline hs-cTnT levels indicates that they may really represent dynamic
50
51 changes in risk stratification.
52
53
54
55
56
57
58
59
60

1
2
3
4 In contrast to the strong associations with mortality and MACE, hs-cTnT
5
6 concentration was not associated with stroke occurrence after adjustment for multiple
7
8 variables. There are several potential explanations for this finding. First, cardiac
9
10 troponin specially reflects myocardial necrosis or subclinical myocardial injury. Some
11
12 previous studies indicate that structural heart abnormalities are more powerful
13
14 determinants of myocardial injury among participants in the general population than
15
16 coronary atherosclerosis.³³⁻³⁴ Second, the Atherosclerosis Risk in Communities
17
18 (ARIC) Study³⁵ showed that elevated plasma hs-cTnT levels were associated with
19
20 increased risk of non-lacunar ischemic strokes, and especially cardioembolic stroke,
21
22 but not with hemorrhagic stroke in the general population. Epidemiological data has
23
24 demonstrated that there are differences in incidence rates of stroke subtypes between
25
26 Chinese and western populations. Intracerebral hemorrhage (ICH) accounts for only
27
28 10-15% of strokes in most western populations,³⁶ whereas up to 55% of strokes in the
29
30 Chinese population are ICH.³⁷ Although analysis for likely ischemic stroke as an end
31
32 point had also been carried out (data not shown), the number of ischemic cause was
33
34 less than one half of all strokes, and it was impossible to obtain an evident difference
35
36 in the results.
37
38
39
40
41
42
43
44

45
46 Our study also has several limitations. First, cardiovascular treatment has
47
48 changed over time and it is possible that more prevalent use of medicines such as
49
50 statins and antiplatelet drugs could have lowered the predictive value of hs-cTnT.
51
52
53 Second, we lack echocardiographic and coronary artery imaging data and thus, can
54
55 not provide causal explanations for the associations between hs-cTnT level , cardiac
56
57
58
59
60

1
2
3
4 abnormalities, and outcomes. Third, the incidence rate of adverse events was
5
6 relatively low in this cohort and hs-cTnT were detected in a considerable proportion,
7
8 which limits its potential for long-term predictive usefulness. Finally, the study
9
10 population was restricted to Chinese Han origin inhabitant. Therefore, extrapolation of
11
12 our results to other demographic groups should be done with caution. The predictive
13
14 value of hs-cTnT needs to be further validated in other observational studies.
15
16
17
18

19 **Conclusion**

20
21 In this prospective cohort of community-dwelling population, we found both
22
23 baseline and changes in cardiac troponin T detected by a highly sensitive assay were
24
25 independently associated with adverse outcomes. The results suggest that cTnT may
26
27 be an important biomarker in the prediction of mortality and cardiovascular events in
28
29 apparently healthy individuals. Further investigations therefore are warranted to
30
31 elucidate mechanisms for cTnT release in these individuals and to test whether active
32
33 interventions can reduce the associated risk contributed by elevated troponin levels.
34
35
36
37
38
39
40

41 **Contributorship statement:** The manuscript has been read and approved by all
42
43 of the authors. All authors contributed to the intellectual development of this paper.

44
45 Conceived and designed the experiments: Ping Ye. Performed the experiments:

46
47 Wenkai Xiao, Yuan Liu. Analyzed the data: Wenkai Xiao and Yongyi Bai. Wrote the
48
49 manuscript: Wenkai Xiao. Supervised data collection: Rui Cao, Hongmei Wu.
50
51

52
53 **Competing Interests:** The authors have declared that no competing interests
54
55 exist.
56
57
58
59
60

1
2
3
4 **Funding:** This study was supported by grants from the Key National Basic
5
6 Research Program of China (2012CB517503, 2013CB530804) and the Key Science
7
8 and Technology Foundation of China (2012ZX09303004-002) to P Ye.
9

10
11 **Data sharing statement:** The additional unpublished data from the study are
12
13 available. We can share the original data for this research article.
14

15
16 **Acknowledgements** We thank our colleagues at the Department of Laboratory
17
18 Medicine of the PLA General Hospital for their help with biochemical measurements.
19
20 We are also grateful to all study participants for their rigorous work.
21
22
23
24
25

26 **References**

- 27
28
29 1. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in
30
31 patients with coronary heart disease. *JAMA* 2003;290:898-904.
32
33
34 2. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional
35
36 biomarkers for prediction of incident cardiovascular events in the community. *JAMA*
37
38 2009;302:49-57.
39
40
41 3. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year
42
43 cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics,
44
45 Archiving, and Monograph (MORGAM) biomarker project. *Circulation* 2010;121:
46
47 2388-97.
48
49
50
51 4. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac
52
53 troponin measurement in acute cardiac care. *Eur Heart J* 2010;31: 2197–204.
54
55
56
57 5. Bandstein N, Ljung R, Johansson M, et al. Undetectable High-Sensitivity Cardiac
58
59
60

1
2
3
4 Troponin T Level in the Emergency Department and Risk of Myocardial Infarction. *J*

5
6
7 *Am Coll Cardiol* 2014;63:2569-78.

8
9
10
11 6. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve
12 the prediction of death from cardiovascular causes. *N Engl J Med* 2008;358: 2107–16.

13
14
15
16
17
18
19 7. Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T
20 and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older
21 adults: results from the Rancho Bernardo Study. *J Am Coll Cardiol* 2008;52:450–9.

22
23
24
25
26
27
28 8. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T
29 and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Am Heart J 2013;166:541-8.

9. Masson S, Anand I, Favero C, et al. Serial Measurement of Cardiac Troponin T
Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. *Circulation*
2012;125:280-8.

10. Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T and
secondary events in outpatients with coronary heart disease from the Heart and Soul
Study. *JAMA Intern Med* 2013;173:763–9.

11. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-
sensitivity cardiac troponin T assay. *Clin Chem* 2010;56:254-261.

12. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating
equation for chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17:
2937-44.

13. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for

1
2
3
4 the 21st century: statement for healthcare professionals from the American
5
6 Heart Association/American Stroke Association. *Stroke* 2013;44:2064-89.

7
8
9 14. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary
10
11 heart disease in epidemiology and clinical research studies. *Circulation* 2003;108:
12
13 2543-9.

14
15
16 15. Oemrawsingh RM, Cheng JM, García-García HM, et al. High-sensitivity
17
18 Troponin T in relation to coronary plaque characteristics in patients with stable
19
20 coronary artery disease; results of the ATHEROREMO-IVUS study. *Atherosclerosis*
21
22 2016;247:135-41.

23
24
25
26 16. Giannitsis E, Spanuth E, Horsch A, et al. High-sensitivity cardiac troponin T and
27
28 N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery
29
30 disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC)
31
32 study. *Clin Chem Lab Med* 2013;51:2019-28.

33
34
35
36 17. Rubin J, Matsushita K, Lazo M, et al. Determinants of minimal elevation
37
38 in high-sensitivity cardiac troponin T in the general population. *Clin Biochem* 2016;
39
40 49:657-62.

41
42
43
44 18. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a
45
46 highly sensitive assay predicts coronary heart disease, heart failure, and mortality in
47
48 the Atherosclerosis Risk in Communities Study. *Circulation* 2011;123:1367-76.

49
50
51 19. Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid atrial
52
53 pacing causes troponin T release detectable by a highly sensitive assay: insights from
54
55 a coronary sinus sampling study. *J Am Coll Cardiol* 2011;57:2398-405.

- 1
2
3
4 20. White HD. Pathobiology of troponin elevations: do elevations occur with
5
6 myocardial ischemia as well as necrosis? *J Am Coll Cardiol* 2011;57:2406-8.
7
8
9 21. Røsjø H, Andreassen J, Edvardsen T, et al. Prognostic usefulness of circulating
10
11 high-sensitivity troponin T in aortic stenosis and relation to echocardiographic
12
13 indexes of cardiac function and anatomy. *Am J Cardiol* 2011;108:88-91.
14
15
16 22. Kawasaki T, Sakai C, Harimoto K, et al. Usefulness of High-Sensitivity Cardiac
17
18 Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in
19
20 Patients With Hypertrophic Cardiomyopathy. *Am J Cardiol* 2013;112:867-72.
21
22
23 23. Ravassa S, Kuznetsova T, Varo N, et al. Biomarkers of cardiomyocyte injury and
24
25 stress identify left atrial and left ventricular remodelling and dysfunction: A
26
27 population-based study. *Int J Cardiol* 2015;185:177-85.
28
29
30 24. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures
31
32 of cardiac troponin T using a sensitive assay with incident heart failure and
33
34 cardiovascular mortality in older adults. *JAMA* 2010;304:2494-502.
35
36
37 25. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected
38
39 with a highly sensitive assay and cardiac structure and mortality risk in the general
40
41 population. *JAMA* 2010;304:2503-12.
42
43
44 26. Sze J, Mooney J, Barzi F, et al. Cardiac Troponin and its Relationship to
45
46 Cardiovascular Outcomes in Community Populations – A Systematic Review and
47
48 Meta-analysis. *Heart Lung Circ* 2016;25:217-28.
49
50
51 27. Lazzarino AI, Hamer M, Gaze D, et al. The association between cortisol response
52
53 to mental stress and high-sensitivity cardiac troponin T plasma concentration in
54
55
56
57
58
59
60

1
2
3
4 healthy adults. *J Am Coll Cardiol* 2013; 62:1694-701.

5
6 28. Schnell-Inderst P, Schwarzer R, Göhler A, et al. Prognostic value, clinical
7
8 effectiveness, and cost-effectiveness of high - sensitivity C-reactive protein as a
9
10 marker for major cardiac events in asymptomatic individuals: a health technology
11
12 assessment report. *Int J Technol Assess Health Care* 2010; 26:30-9.

13
14 29. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of N- terminal
15
16 pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk as
17
18 assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2015;
19
20 170:1170-83.

21
22 30. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-
23
24 terminal pro -B type natriuretic peptide are associated with cardiovascular events
25
26 despite the cross- sectional association with albuminuria and glomerular filtration rate.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Eur Heart J 2012; 33:2272-81.

36
37 31. Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury assessed by
38
39 a highly sensitive troponin assay and sudden cardiac death in the community: the
40
41 Cardiovascular Health Study. *J Am Coll Cardiol* 2013;62:2112-20.


42
43 32. Hussein AA, Bartz TM, Gottdiener JS, et al. Serial measures of cardiac troponin
44
45 T levels by a highly sensitive assay and incident atrial fibrillation in a prospective
46
47 cohort of ambulatory older adults. *Heart Rhythm* 2015;12:879-85.

48
49 33. Masson S, Latini R, Mureddu GF, et al. High-sensitivity cardiac troponin T for
50
51 detection of subtle abnormalities of cardiac phenotype in a general population of
52
53 elderly individuals. *J Intern Med* 2013;273:306-17.

- 1
2
3
4 34. de Lemos JA, deFilippi CR. Prevalence and significance of detectable troponins as
5
6 measured by highly sensitive assays in the general population. *Coronary Artery*
7
8 *Disease* 2013;24:705-9.
9
10
11 35. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-Terminal Pro-B-Type
12
13 Natriuretic Peptide, and Incidence of Stroke. The Atherosclerosis Risk in
14
15 Communities Study. *Stroke* 2013; 44:961-7.
16
17
18 36. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke
19
20 statistics-2009 update: a report from the American Heart Association Statistics
21
22 Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:480-6.
23
24
25 37. Yang QD, Niu Q, Zhou YH, et al. Incidence of cerebral hemorrhage in the
26
27 Changsha community. A prospective study from 1986 to 2000. *Cerebrovasc Dis.*
28
29 2004;17:303-13.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


A Major adverse cardiovascular events



No. at risk				
Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

95x106mm (600 x 600 DPI)

B Coronary event




No. at risk

Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

84x98mm (600 x 600 DPI)

C Stroke




No. at risk	0	20	40	60
Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

99x114mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

D All-cause mortality



No. at risk				
Group 1	679	674	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

Figure1. Risk for Cardiovascular Events and All-Cause Mortality by Baseline hs-cTnT Level
Kaplan-Meier survival curves indicating cumulative incidence of MACE (A), Coronary event (B), Stroke (C) and All-cause mortality (D) across baseline hs-cTnT categories. Groups are indicated by colors, P<0.001 for all between-group comparisons by the log-rank test.

113x89mm (600 x 600 DPI)

Supplementary Table1. Characteristics of Study Population between the follow up and lost groups

Characteristics	Baseline population		P value
	Follow up group (n=1499)	lost to follow up group (n=181)	
Demographic			
Age (years)	61.4±11.4	57.6±10.5	<0.01
Male Sex n (%)	629 (42.0)	83(45.9)	0.316
BMI (kg/m ²)	25.6±3.3	25.8±3.4	0.273
Medical history			
Hypertension n (%)	690(46.0)	72(39.8)	0.111
Diabetes mellitus n (%)	292(19.5)	30(16.6)	0.348
Current smoking n (%)	247(16.5)	35(19.3)	0.331
Systolic BP (mm Hg)	132.7±17.0	130.6±16.7	0.136
Diastolic BP (mm Hg)	76.6±10.3	77.8±10.7	0.077
Laboratory values			
FBG (mmol/L)	5.4±1.6	5.3±1.5	0.474
PBG (mmol/L)	8.0±4.2	7.5±3.7	<0.05
Total cholesterol (mmol/L)	5.1±0.9	5.0±0.9	0.321
Triglycerides (mmol/L)	1.8±1.2	1.9±1.1	0.054
LDL cholesterol (mmol/L)	3.0±0.7	2.9±0.6	0.21
HDL cholesterol (mmol/L)	1.4±0.3	1.4±0.3	0.386
Uric acid (μmol/L)	291.4±73.3	276.9±70.8	<0.01
eGFR (mL/min/1.73m ²)	88.9±15.5	92.1±16.0	0.009
NT-proBNP (pg/mL)	41.7(19.8,81.9)	37.4(17.3,73.9)	<0.01
Hs-CRP (mg/L)	2.3 (1.4, 3.5)	2.2 (1.3, 3.4)	0.189
Medication use			
Antihypertensives n (%)	528 (35.2)	55 (30.4)	0.197
Antidiabetic n (%)	189 (12.6)	19 (10.5)	0.415

Lipid lowering	n (%)	262 (17.5)	29(16.0)	0.625
Aspirin	n (%)	360 (24.0)	37 (20.4)	0.285

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	5	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5-6	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7	
Bias	9	Describe any efforts to address potential sources of bias		
Study size	10	Explain how the study size was arrived at		

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	9
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-13
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14-16
		(b) Report category boundaries when continuous variables were categorized	15
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
Discussion			
Key results	18	Summarise key results with reference to study objectives	18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	22
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

BMJ Open

Association of High-Sensitivity Cardiac Troponin T with Mortality and Cardiovascular Events in a Community-Based Prospective Study in Beijing

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013431.R2
Article Type:	Research
Date Submitted by the Author:	24-Feb-2017
Complete List of Authors:	Xiao, Wenkai Cao, Ruihua; Chinese PLA General Hospital, Geriatric Cardiology Liu, Yuan; Chinese PLA General Hospital, Geriatric Cardiology Wang, Fan; Chinese PLA General Hospital, Geriatric Cardiology Bai, Yongyi; Chinese PLA General Hospital, Geriatric Cardiology Wu, Hongmei; Chinese PLA General Hospital, Geriatric Cardiology Ye, Ping; Chinese PLA General Hospital, Geriatric Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology
Keywords:	Biomarkers, Cardiac Epidemiology < CARDIOLOGY, risk assessment, prognosis

SCHOLARONE™
Manuscripts

1
2
3
4 **Association of High-Sensitivity Cardiac Troponin T with Mortality**
5
6 **and Cardiovascular Events in a Community-Based Prospective Study**
7
8 **in Beijing**
9

10
11
12
13
14 Wenkai Xiao, Ruihua Cao, Yuan Liu, Fan Wang, Yongyi Bai, Hongmei Wu, Ping Ye*

15
16 Department of Geriatric Cardiology, Chinese PLA General Hospital, No. 28, Fuxing
17
18 Road, Beijing, 100853, China
19

20
21 Correspondence to Ping Ye, Department of Geriatric Cardiology, Chinese PLA
22
23 General Hospital, Beijing, 100853, China
24

25
26 Tel:+86-10-66876369; Fax:+86-10-66876349; E-mail: yeping301@sina.com
27

28
29 **Keywords:** Biomarkers; High-sensitivity cardiac troponin T; Cardiovascular diseases;
30
31 Prognosis; Risk assessment.
32

33
34 **Word count:** 5860
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: The prognostic value of cardiac troponins in apparently healthy populations is not well established. The aim of this study was to investigate the prognostic properties of high-sensitivity cardiac troponin T (hs-cTnT) for long-term adverse outcomes.

Setting: A community-dwelling prospective survey of residents from two communities in Beijing.

Participants: From September 2007 to January 2009, 1680 participants were initially enrolled. Of these, 1499 (870 females, mean age: 61.4 years) participants completed the survey and were followed up for a median of 4.8 years (interquartile range: 4.5–5.2).

Outcome measures: The primary outcome was the occurrence of all-cause mortality and major cardiovascular events.

Results: Overall, 820 individuals (54.7%) had detectable hs-cTnT levels. During the follow-up, 52 participants (3.5%) died, 154 (10.3%) had major cardiovascular events, and 99 (6.6%) experienced new-onset coronary events. Compared with those with undetectable hs-cTnT levels, participants with hs-cTnT levels in the highest category (≥ 14 ng/L) had a significantly increased risk for all-cause mortality (adjusted hazard ratio [aHR] : 2.07, 95% confidence interval [CI]: 1.05–3.01), major cardiovascular events (aHR: 3.27, 95% CI: 1.88–5.70), and coronary events (aHR: 4.50, 95% CI: 2.26–9.02) in covariate-adjusted analyses. No differences in stroke incidence were found (aHR: 1.27; 95% CI: 0.69–2.62). Also, significant associations

1
2
3
4 were presented when hs-cTnT levels were modelled as a continuous variable and
5
6 when analysing changes in hs-cTnT levels over time with adverse outcomes. The
7
8 addition of troponin T levels to clinical variables led to significant increases in risk
9
10 prediction with a marked improvement in the c-statistic (P=0.003 or lower).
11
12

13
14 **Conclusions:** In this cohort of individuals from a community-based population,
15
16 cardiac troponin T levels measured with a highly sensitive assay were associated with
17
18 increases in the subsequent risk for all-cause mortality and major cardiovascular
19
20 events. These results might support screening for at-risk individuals.
21
22
23
24
25
26
27
28

29 **Strengths and limitations of this study**

- 30
31 ■ Evaluating the prognostic properties of both baseline hs-cTnT and change in
32
33 hs-cTnT for long-term adverse outcomes in a large community-dwelling study.
34
35
- 36
37 ■ Reliably detecting minimal subclinical myocardial injury in an apparently healthy
38
39 population over a wide age range.
40
- 41
42 ■ Due to the lack of echocardiographic and coronary artery imaging data, no causal
43
44 explanations on the associations between hs-cTnT and outcomes could be
45
46 provided.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Cardiovascular disease (CVD) is still the primary cause of morbidity and mortality worldwide. There is concordant evidence that prevention is the key to lessening the CVD burden, but predicting the risk of adverse cardiovascular events in low- to intermediate-risk individuals is a considerable challenge.¹ This subpopulation is at risk for developing CVD but is not identified during the early stages by current risk screening methods.²⁻³ Circulating biomarkers can be an important supplemental screening tool, and troponins are one of the most interesting biomarkers in this context. Cardiac troponin T (cTnT) is a regulatory protein that is expressed by cardiac myocytes and is released in the setting of myocardial injury.⁴⁻⁵ As a sensitive and specific marker of cardiomyocyte damage, cTnT is typically used to exclude or confirm the diagnosis of acute myocardial infarction in the clinical setting.

However, cTnT levels can also be elevated and clinically meaningful in the absence of myocardial ischaemia. Detectable levels of cTnT can also be useful for detecting subclinical CVD and assessing CVD risk in the general population. However, the use of cTnT for clinical applications is limited, as it is only detectable in a small percentage of the general population using standard assays.⁶⁻⁷ Recently, a highly sensitive cTnT (Hs-cTnT) assay has been developed, which can detect concentrations that are 10-fold lower than those detectable with the standard fourth-generation assay. The introduction of this new assay has enabled the detection of very low levels of circulating cTnT, even in an asymptomatic general population.⁸

Levels of cTnT, below the detection limit of standard assays, have been shown to

1
2
3
4 be independently associated with adverse cardiovascular events in patients with heart
5
6 failure (HF) ⁹ or stable coronary heart disease (CHD). ¹⁰ However, the clinical
7
8 significance of detectable cTnT with the use of the new assay in the apparently
9
10 healthy population has not been well established. The main objective of this study was
11
12 to investigate the prognostic value of minimally detectable hs-cTnT levels in
13
14 predicting adverse clinical events in a population of community-based subjects.
15
16
17

18 19 **Methods**

20 21 **Study population**

22
23 This was a prospective observational study of people living in the Pingguoyuan
24
25 area of the Shijingshan district, which is a metropolitan area of Beijing, China.
26
27
28 Between September 2007 and January 2009, all permanent residents of the Han origin,
29
30 aged 45 years or older (range 45–91 years), from two communities, were invited to
31
32 participate in a health survey that focused on identifying CVD risk factors. Thirty-one
33
34 subjects with bedridden status, mental illness, and severe systemic diseases were
35
36 excluded from enrolment. Then, 1832 participants were included and asked to
37
38 complete questionnaires. Of these, 152 participants with overt CVD (defined as a
39
40 composite of CHD [myocardial infarction, angina pectoris, or coronary insufficiency],
41
42 cerebrovascular disease [stroke or transient ischaemic attack], congestive HF, or
43
44 peripheral vascular disease) were excluded. Adequate baseline measurements and
45
46 cardiac biomarkers were obtained in 1680 participants. After the initial evaluation, the
47
48 recruited subjects were contacted every 2 years for follow-up, and the last follow-up
49
50 visits were conducted through September 30, 2013. The median follow-up was 4.8
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (interquartile range: 4.5–5.2) years. In our investigation, 181 participants were lost to
5
6 follow-up (Supplementary Table 1) and were excluded from the study. Complete data
7
8 were acquired from 1499 participants (return rate: 89.2%). All participants provided
9
10 written informed consent at the time of enrolment, and the study was approved by the
11
12 Ethics Committee of the Chinese People’s Liberation Army General Hospital.
13
14

15 16 **Data collection**

17
18 Baseline characteristics were collected using self-reported standardized
19
20 questionnaires that included demographics, life-style information, medical history,
21
22 and medication use. Anthropometrical measurements were obtained by trained
23
24 medical doctors, and the body mass index (BMI) was derived from heights and
25
26 weights that were measured in participants wearing light clothing and no shoes. Blood
27
28 pressures were measured twice on the right arm after 5 minutes of rest in a sitting
29
30 position, and the mean of two readings was used for further analysis. Participants
31
32 were followed up for clinical outcomes by interview. Outcome measures were the
33
34 occurrences of all-cause mortality and major adverse cardiovascular events (MACE).
35
36 New events were validated by obtaining medical records and adjudicated by two
37
38 independent and blinded reviewers. In the analyses, survival time was defined as the
39
40 period from the date of baseline blood sample collection to the date of the first
41
42 adverse event or end of follow-up.
43
44
45
46
47
48
49

50 51 **Biomarker assays**

52
53 At the time of enrolment, baseline blood samples were collected from
54
55 participants between 8 AM and 10 AM after at least 12 hours of overnight fasting.
56
57
58
59
60

1
2
3
4 Follow-up measurements were performed on blood samples, which were collected 4
5
6 to 5 years later. Serum aliquots were frozen at -80°C until further analyses in a central
7
8 laboratory. Concentrations of blood glucose (fasting and 2 hours after an oral glucose
9
10 tolerance), total cholesterol (TC), triglycerides (TGs), high-density lipoprotein
11
12 cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid, and
13
14 serum creatinine were measured by routine laboratory analysis.
15
16
17

18
19 Hs-cTnT levels were measured by an electrochemiluminescence immunoassay
20
21 method using an Elecsys Troponin T highly sensitive assay (Roche Diagnostics
22
23 GmbH, Mannheim, Germany) on the Modular Analytics E170 autoanalyser (Roche
24
25 Diagnostics). The lower detection limit of the novel assay was 3 ng/L, and the 99th
26
27 percentile value in apparently healthy individuals has been reported to be 14 ng/L.¹¹
28
29 N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations were
30
31 determined using an electrochemiluminescence immunoassay (Roche Diagnostics
32
33 GmbH) on the Roche analyser. Levels of high-sensitivity C-reactive protein (hs-CRP)
34
35 were measured with the use of an immunoturbidimetric assay (Siemens Healthcare
36
37 Diagnostics, IN, USA) on a Dimension RxL Max analyser (Siemens Healthcare
38
39 Diagnostics).
40
41
42
43
44
45

46
47 Estimated glomerular filtration rate (eGFR) was calculated using the Chinese
48
49 Modification of Diet in Renal Disease equation. Details of the computing equation
50
51 have been published elsewhere.¹²
52
53

54 **Definition of end points**

55

56
57 For outcomes, we used the incidence of mortality and CVD morbidity after the
58
59
60

1
2
3
4 baseline screening. All-cause mortality was determined by review of death certificates.

5
6 The definition of MACE comprised nonfatal myocardial infarction, newly diagnosed
7
8 CHD (identified by coronary artery imaging or receiving coronary revascularization),
9
10 stroke (ischaemic or haemorrhagic), and cardiovascular mortality. Major coronary
11
12 events were defined as nonfatal myocardial infarction, newly diagnosed CHD, and
13
14 CHD death. Stroke was characterized as a neurological deficit attributed to an acute
15
16 focal injury of the central nervous system by a vascular cause, including cerebral
17
18 infarction, intracerebral haemorrhage, and subarachnoid hemorrhage.¹³

19
20 Cardiovascular mortality was defined as mortality related to atherosclerotic heart
21
22 disease (fatal myocardial infarction and definite fatal CHD), mortality following
23
24 cerebrovascular disease, or mortality from HF and other CVD. Nonfatal myocardial
25
26 infarction was defined by the American Heart Association diagnostic criteria.¹⁴
27
28
29
30
31
32

33 **Statistical analysis**

34
35
36 Continuous variables are reported as mean \pm standard deviation (SD) or median
37
38 (interquartile range), and categorical variables are presented as counts and
39
40 percentages. Hs-cTnT was modelled as both a categorical and continuous variable.
41
42 For the analyses of hs-cTnT as a categorical variable, participants were divided into
43
44 four categories. Participants with undetectable hs-cTnT were placed in the first
45
46 category as the reference group. Those with hs-cTnT levels greater than or equal to
47
48 the previously reported 99th percentile value (14 ng/L)¹¹ were placed in the fourth
49
50 category, and those with levels between 3 and 14 ng/L were divided into two groups
51
52 for categories 2 and 3, respectively, based on the median value of hs-cTnT.
53
54
55
56
57
58
59
60

1
2
3
4 Demographic and clinical variables were compared across hs-cTnT categories using
5
6 the one-way analysis of variance tests for continuous measures, Cuzik's
7
8 nonparametric trend test for nonnormally distributed variables, and chi-squared tests
9
10 for categorical variables.
11
12

13
14 The cumulative incidence of MACE and all-cause mortality for each category of
15
16 hs-cTnT concentration were evaluated using the Kaplan-Meier method and compared
17
18 with the log-rank test. Multivariable Cox proportional hazards regression models
19
20 were used to analyse associations of hs-cTnT categories with outcomes, and category
21
22 1 was used as the reference. The models were incrementally adjusted for
23
24 demographics, traditional cardiovascular risk factors, renal function, and other
25
26 biomarkers (Hs-CRP and NT-proBNP). We also carried out an exploratory analysis,
27
28 in which cTnT was regarded as a continuous variable, and the relationship between
29
30 natural logarithm-transformed hs-cTnT values and end points was assessed. In this
31
32 analysis, values of cTnT that were below the lower limit of detection were assigned to
33
34 1.5 ng/L (i.e., one-half of the lower limit of detection).
35
36
37
38
39
40

41
42 In view of the markedly skewed distribution of cTnT, changes in concentrations
43
44 over time were calculated as the difference between the natural logarithm of the
45
46 concentrations at follow-up and baseline. The association between changes in
47
48 hs-cTnT levels and outcomes were also evaluated in Cox proportional hazards models.
49
50 The change in hs-cTnT levels was entered as a continuous variable and was adjusted
51
52 for the baseline concentration of hs-cTnT and other relevant variables.
53
54
55

56
57 The discriminative capacity of a model with and without cTnT was estimated as
58
59
60

1
2
3
4 C-statistics. The area under the receiver operating characteristic curve summarised the
5
6 diagnostic discrimination. All data were analysed using the SPSS statistical package
7
8 software (version 17.0). A two-sided value of $P < 0.05$ was considered statistically
9
10 significant.

11 12 13 **Results**

14 15 **Participant characteristics**

16
17 For the present analyses, 1499 participants were included. The mean (\pm SD)
18
19 age of participants at enrolment was 61.4 ± 11.4 years and 58.0% were women.
20
21 Detectable baseline cTnT levels were found in 820 individuals (54.7%; ranged from 3
22
23 to 176.4 ng/L) and were equal to or higher than 14 ng/L in 172 participants (11.5%).
24
25 Table 1 shows baseline characteristics by hs-cTnT categories. Compared with those
26
27 with lower cTnT levels, individuals with higher levels were older, more likely to be
28
29 male, more frequently hypertensive and diabetic, had lower eGFR and HDL-C levels,
30
31 and had higher uric acid and NT-proBNP levels. The use of antihypertensive drugs,
32
33 antidiabetic drugs, and aspirin varied across levels of hs-cTnT.
34
35
36
37
38
39
40

41 42 **Outcomes by baseline hs-cTnT**

43
44 Over a median follow-up period of 4.8 years (interquartile range: 4.5–5.2), 154
45
46 participants experienced new-onset MACE (including 99 coronary events and 61
47
48 strokes, and some participants had more than one event). Fifty-two deaths occurred
49
50 from any cause. The cumulative incidences of MACE and all-cause mortality by
51
52 hs-cTnT categories are shown in Figure 1. As demonstrated by the Kaplan-Meier
53
54 survival analysis, there was a graded increase in the probability of adverse clinical
55
56
57
58
59
60

1
2
3
4 events across categories. The unadjusted incidence rate for MACE ranged from 3.7%
5
6 in participants with undetectable hs-cTnT levels to 23.3% in participants in the
7
8 highest category ($P<0.001$, log-rank test). Similar trends were discovered for coronary
9
10 events, stroke, and all-cause mortality, and a particularly high risk was found for
11
12 participants in the highest category.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of the study population by baseline high-sensitivity troponin T levels

Characteristics	Hs-cTNT Group (ng/L)				P value for Trend
	Group 1 <3.00 (n = 679)	Group 2 3.00-6.21 (n=324)	Group 3 6.22-<14 (n= 324)	Group4 ≥14 (n = 172)	
Demographics					
Age (years)	58.6±10.3	63.1±10.7	64.2±12.4	61.8±11.5	<0.001
Male Sex; n (%)	202 (29.7)	163 (50.3)	170 (52.5)	94 (54.7)	<0.001
BMI (kg/m ²)	25.5±3.5	25.7±3.2	25.6±3.3	25.8±3.5	0.498
Medical history					
Hypertension; n (%)	258 (38.0)	159 (49.1)	176 (54.3)	97 (56.4)	<0.001
Diabetes mellitus; n (%)	99 (14.6)	72 (22.2)	76 (23.5)	45 (26.2)	<0.001
Current smoking; n (%)	85 (12.5)	69 (21.3)	62 (19.1)	31(18.0)	0.003
Systolic BP (mm Hg)	131.5±16.5	132.7±17.3	132.8±17.2	133.2±17.1	0.041
Diastolic BP (mm Hg)	77.1±9.7	77.3±10.0	76.4±10.5	76.1±11.1	0.372
Laboratory values					
FBG (mmol/L)	5.3±1.4	5.3±1.5	5.5±1.7	5.8±1.9	0.076
PBG (mmol/L)	7.5±3.7	7.1±3.2	8.1±4.3	8.9±4.4	<0.001

Total cholesterol (mmol/L)	5.1±0.9	5.1±0.9	5.1±0.9	5.0±0.9	0.464
Triglycerides (mmol/L)	1.8±1.1	1.7±1.1	1.7±1.0	2.0±1.4	0.04
LDL cholesterol (mmol/L)	3.0±0.7	2.9±0.7	3.0±0.7	3.0±0.7	0.136
HDL cholesterol (mmol/L)	1.4±0.4	1.4±0.3	1.3±0.4	1.3±0.4	0.001
Uric acid (µmol/L)	279.0±68.2	295.9±73.3	301.2±75.4	309.5±76.2	<0.001
eGFR (mL/min/1.73m ²)	90.1±14.5	88.7±13.4	87.5±15.2	84.7±16.5	0.001
NT-proBNP (pg/mL)	37.2 (17.9, 75.3)	38.9 (17.9, 74.4)	46.6 (22.3, 90.1)	49.3 (17.1, 112)	0.003
Hs-CRP (mg/L)	2.4 (1.3, 3.4)	2.3 (1.4, 3.4)	2.2 (1.5, 3.5)	2.4 (1.6, 3.6)	0.383
Medication use					
Antihypertensives; n (%)	187 (27.5)	122 (37.7)	139 (42.9)	80 (46.5)	<0.001
Antidiabetics; n (%)	64 (9.4)	44 (13.6)	52 (16.0)	29 (16.9)	0.0028
Lipid lowering drugs; n (%)	109 (16.1)	61 (18.8)	58 (17.9)	34 (19.8)	0.149
Aspirin; n (%)	137 (20.2)	79 (24.4)	89 (27.5)	55 (31.9)	<0.001

Values are reported as n (%), mean ± SD, or median (interquartile range). BMI=body mass index; BP=blood pressure; eGFR =estimated glomerular filtration rate; FBG=fasting blood glucose;

HDL= high-density lipoprotein; Hs-CRP = high-sensitivity C-reactive protein; LDL = low- density lipoprotein; PBG= postprandial blood glucose; NT-proBNP = N-terminal pro-type B

natriuretic peptide.

Associations of baseline hs-cTnT levels with MACE and all-cause mortality

In a series of Cox proportional hazards models adjusting for age and gender (model 1), and further adjusting for traditional cardiovascular risk factors (model 2), higher hs-cTnT categories demonstrated a graded association with MACE. Only a modest attenuation of the hazards was found with further adjustment for renal function (model 3). Although a significant attenuation was discovered with additional adjustments for hs-CRP and NT-proBNP levels (model 4), hs-cTnT levels in the third category (hazard ratio [HR]: 2.31, 95% CI: 1.39–3.84) and fourth category (HR: 3.27, 95% CI: 1.88–5.70) remained independently associated with MACE in the fully adjusted models. Participants in hs-cTnT categories 3 and 4 also had a significantly higher risk of coronary events compared with participants with undetectable levels (HRs of 2.76 [95% CI: 1.44–5.31] and 4.50 [95% CI: 2.26–9.02], respectively, in model 4; Table 2). However, associations of hs-cTnT levels with stroke events were markedly attenuated and no longer significant after adjusting for NT-proBNP (model 4; Table 2). Membership in the highest hs-cTnT category was independently associated with all-cause mortality (HR: 2.07, 95% CI: 1.05–3.01) in both univariate and multivariate analyses.

In an exploratory research of hs-cTnT as a continuous variable after natural logarithmic transformation, we found a continuous association with MACE incidence (per one- logarithmic unit increment; HR: 1.67; 95% CI, 1.04–2.68; $P < 0.001$), coronary events (HR: 1.68; 95% CI, 1.35–2.08; $P < 0.001$) or all-cause mortality (HR:

1.50; 95% CI, 1.26–1.79; P=0.003) in fully multivariate models encompassing the variables described in Table 2. No association between stroke risk and cTnT as a continuous variable was found in the final adjusted models (HR: 1.06; 95% CI, 0.87–1.32; P=0.17).

Table 2. Cox proportional hazards models analysis for associations between baseline hs-cTnT levels and outcomes

	Hazard Ratio (95% Confidence Interval)			
	Group 1 <3.00 ng/L	Group 2 3.0–6.21 ng/L	Group 3 6.22–<14 ng/L	Group 4 ≥14 ng/L
No.	679	324	324	172
MACE	n=25 (3.7%)	n=30 (9.3%)	n=59 (18.2%)	n=40 (23.3%)
Model 1	1[Reference]	1.65 (0.97–2.81)	2.65 (1.64–4.27)	4.20 (2.51–7.02)
Model 2	1[Reference]	1.52 (0.89–2.59)	2.41 (1.48–3.91)	3.82 (2.27–6.43)
Model 3	1[Reference]	1.52 (0.89–2.61)	2.38 (1.47–3.88)	3.79 (2.26–6.39)
Model 4	1[Reference]	1.68 (0.97–2.92)	2.31 (1.39–3.84)	3.27 (1.88–5.70)
Coronary event	n=14 (2.1%)	n=17 (5.3%)	n=41 (12.7%)	n=27 (15.7%)
Model 1	1[Reference]	1.69 (0.83–3.44)	3.39 (1.82–6.29)	5.23 (2.7–10.14)
Model 2	1[Reference]	1.61 (0.78–3.29)	3.25 (1.74–6.07)	5.5 (2.84–10.64)
Model 3	1[Reference]	1.57 (0.76–3.22)	3.09 (1.65–5.79)	5.14 (2.65–9.98)
Model 4	1[Reference]	1.42 (0.71–2.89)	2.76 (1.44–5.31)	4.50 (2.26–9.02)
Stroke event	n=11 (1.6%)	n=13 (4.0%)	n=20 (6.2%)	n=17 (9.9%)
Model 1	1[Reference]	1.59 (0.71–3.57)	1.94 (0.91–4.14)	3.84 (1.75–8.43)
Model 2	1[Reference]	1.47 (0.65–3.29)	1.77 (0.83–3.79)	3.19 (1.42–7.16)
Model 3	1[Reference]	1.47 (0.65–3.31)	1.70 (0.79–3.66)	3.16 (1.41–7.10)
Model 4	1[Reference]	1.03 (0.50–2.09)	1.13 (0.57–2.14)	1.27 (0.69–2.62)
All-cause mortality	n=8 (1.2%)	n=7 (2.2%)	n=16 (4.9%)	n=21 (12.2%)
Model 1	1[Reference]	1.13 (0.41–3.14)	1.99 (0.83–4.76)	6.14 (2.61–14.46)

Model 2	1[Reference]	1.13 (0.41–3.14)	1.78 (0.73–4.35)	4.87 (1.99–11.88)
Model 3	1[Reference]	1.14 (0.41–3.16)	1.79 (0.73–4.38)	4.87 (1.99–11.88)
Model 4	1[Reference]	1.01 (0.40–1.15)	1.09 (0.43–2.76)	2.07 (1.05–3.01)

Abbreviations: MACE, major adverse cardiovascular event.

Models are defined as follows: model 1=adjusted for age and gender; model 2=adjusted for model 1 + presence of hypertension or diabetes mellitus, current smoking status, systolic blood pressure, postprandial blood glucose, total cholesterol, high-density lipoprotein cholesterol, antihypertensive medication use, and antidiabetic medication use; model 3= adjusted for model 2 + estimated glomerular filtration rate; model 4= adjusted for model 3 + high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide (both after logarithmic transformation).

Changes in hs-cTnT concentration during follow-ups and subsequent events

Table 3 presents the results of Cox regression analysis for subsequent events in relation to changes in hs-cTnT concentration as a continuous variable. Changes in hs-cTnT concentration were strongly associated with subsequent events except for stroke, even in multivariable analyses that additionally adjusted for baseline hs-cTnT levels. In the fully adjusted models, the HRs for MACE, and coronary events for every unit increasing in hs-cTnT concentration, were 1.35 (95% CI: 1.08–1.68, P=0.008) and 1.44 (95% CI: 1.17–1.77, P=0.001), respectively. However, an increase in hs-cTnT concentration was not significantly associated with stroke events (HR: 1.02, 95% CI: 0.64–2.19, P=0.242).

Table 3. Association of changes in hs-cTnT concentrations with subsequent events

	Multivariable-adjusted HR	95% CI	P Value
--	---------------------------	--------	---------

MACE	1.35	1.08–1.68	0.008
Coronary event	1.44	1.17–1.77	0.001
Stroke event	1.02	0.64–2.19	0.242

Abbreviations: HR, hazard ratio; CI, confidence interval; MACE, major adverse cardiovascular event. Data are presented as hazard ratios and 95% confidence intervals for a 1-unit increase in the change in hs-cTnT on a log scale. Multivariable model was adjusted for the covariates listed for Model 4 in Table 2, plus the baseline hs-cTnT level.

Hs-cTnT and risk prediction

Hs-cTnT provided incremental prognostic information regarding the three endpoints when added to a model based on established risk indicators (Table 4). The addition of hs-cTnT increased the c-statistic from 0.671 to 0.698 (P=0.003) for the prediction of all-cause mortality. The prediction of MACE also improved from 0.702 to 0.734 (P<0.001).

Table 4. Discrimination of adverse outcomes with the addition of hs-cTnT to the clinical risk factor model

Endpoint	c-statistic (95%CI)		P Value
	Clinical Model	Clinical Model + hs-cTnT	
All-cause mortality	0.671 (0.646–0.704)	0.698 (0.680–0.725)	0.003
MACE	0.702 (0.680–0.726)	0.734 (0.714–0.758)	<0.001
Coronary event	0.713 (0.701–0.735)	0.749 (0.729–0.768)	<0.001
Stroke event	0.683 (0.665–0.709)	0.697 (0.674–0.729)	0.09

Abbreviations: CI, confidence interval; MACE, major adverse cardiovascular event.

1
2
3
4 The clinical risk factor model included age, gender, body mass index, current smoking status, diabetes mellitus,
5
6 systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and
7
8 estimated glomerular filtration rate.
9

10 11 **Discussion**

12
13
14 The main purpose of the current study was to evaluate the usefulness of
15
16 measuring hs-cTnT for predicting major cardiovascular events and all-cause mortality
17
18 in a community-dwelling study of general population. There were several valuable
19
20 findings. First, the up-to-date generation of cTnT assay allowed for minimal
21
22 subclinical myocardial injury to be reliably detected in some individuals of a general
23
24 population covering a wide age range. There was no need to restrict the study to
25
26 morbid or high-risk individuals. Second, baseline and kinetic changes in hs-cTnT
27
28 concentration were powerful and independent predictors of long-term MACE and
29
30 all-cause mortality. Finally, these risk predictions were persistent, even after adjusting
31
32 for traditional cardiovascular risk factors and biomarkers of inflammation and cardiac
33
34 wall strain.
35
36
37
38
39

40
41 Cardiac troponins are generally the preferred biomarkers of myocardial
42
43 necrosis and are typically used in the diagnosis of acute coronary syndromes. But the
44
45 recently available hs-cTnT assay has allowed for the detection of much lower
46
47 concentrations of circulating cTnT. More recent observations using this new assay
48
49 have shown that very low levels of circulating cTnT can be detectable, these levels of
50
51 circulating cTnT can provide information about coronary plaque characteristics and
52
53 mortality in patients with stable CHD,¹⁵⁻¹⁶ and very low levels of circulating cTnT
54
55
56
57
58
59
60

1
2
3
4 can even be detected in the general population.¹⁷⁻¹⁸ The exact mechanisms of troponin
5
6 release in apparently healthy individuals are not well clarified. One possibility is the
7
8 existence of asymptomatic cardiac ischaemia with minimal myocardial injury, which
9
10 results in the asymptomatic release of troponins.¹⁹ Other mechanisms include
11
12 cardiomyocyte apoptosis,²⁰ physiological cell turnover,²¹ or subclinical cardiac
13
14 structural or functional abnormalities.²²⁻²³
15
16
17
18

19 The prognostic implications of hs-cTnT assays among apparently healthy
20
21 individuals have recently been explored in three large cohort studies.^{18, 24-25} However,
22
23 these studies focused on middle-aged and elderly subjects from western countries.
24
25 Our study extends the findings to the Asian population and demonstrates the
26
27 significance of the hs-cTnT assay in risk assessment. To the best of our knowledge,
28
29 this is the first study to evaluate the potential utility of the hs-cTnT assay in a Chinese
30
31 population. One important finding is the observation that the presence of an elevated
32
33 hs-cTnT level (in the highest category) was associated with adverse outcomes
34
35 regarding all-cause mortality and MACE. However, there were no associations
36
37 between minimally detectable hs-cTnT levels, especially those below 6.2 ng/L, and
38
39 death or MACE. It has been proposed that such levels may be physiological,
40
41 reflecting normal myocardial cell turnover and apoptosis within the senescent heart
42
43 tissue.²⁶ The levels may also be a result of the cortisol response to mental stress in
44
45 healthy adults.²⁷ Further research is required to determine which hs-cTnT threshold
46
47 value may best be used in risk prediction.
48
49
50
51
52
53
54

55 Although other biomarkers, such as hs-CRP and NT-proBNP, have been used to
56
57
58
59
60

1
2
3 identify apparently healthy individuals who are at increased CVD risk,²⁸⁻²⁹ our
4
5 investigation indicates that hs-cTnT was also independent of these biomarkers. In this
6
7 cohort, although associations with death and cardiovascular events were significantly
8
9 attenuated after additional adjustments for levels of NT-proBNP, hs-cTnT remained
10
11 independently predictive of end points in the final model, suggesting that the two
12
13 biomarkers convey slightly different information for cardiac structural and functional
14
15 abnormalities. The HRs remained statistically significant after adjusting for traditional
16
17 cardiovascular risk factors and renal function, and were consistent with results from
18
19 other studies.^{8,30} These data indicate that very low levels of cTnT may be used to
20
21 identify subclinical myocardial injury and estimate the risk of cardiovascular events,
22
23 which are currently not fully estimated by established methods. Also, associations of
24
25 hs-cTnT concentration with all-cause mortality and MACE were consistent in the
26
27 stratification analysis defined by sex.
28
29
30
31
32
33
34
35

36 Our data also suggest that even minimal changes in low levels of cTnT have
37
38 prognostic characteristics and can help to identify individuals at long-term risk for
39
40 adverse events. There seemed to be a dose-dependent relationship between increased
41
42 hs-cTnT and increased risk. Similarly, DeFilippi et al.²⁴ have reported that changes in
43
44 cTnT concentrations, which were determined with a highly sensitive assay, are
45
46 significantly associated with incident HF events and cardiovascular death in
47
48 community-based older adults. Furthermore, in a prospective cohort of ambulatory
49
50 older adults, a strong increase in the risk of sudden cardiac death³¹ and incident atrial
51
52 fibrillation³² was associated with changes in hs-cTnT concentrations over time.
53
54
55
56
57
58
59
60

1
2
3
4 Although these changes may reflect normal physiological variation, their relation to
5
6 future adverse events, regardless of baseline hs-cTnT levels, indicates that they may
7
8 really represent dynamic changes in risk stratification.
9

10
11 In contrast to the strong associations with mortality and MACE, hs-cTnT
12
13 concentration was not associated with stroke occurrence after adjusting for multiple
14
15 variables. There are several potential explanations for this finding. First, cardiac
16
17 troponin specifically reflects myocardial necrosis or subclinical myocardial injury.
18
19 Some studies have indicated that in comparison to coronary atherosclerosis, structural
20
21 heart abnormalities are more powerful determinations of myocardial injury in the
22
23 general population.³³⁻³⁴ Second, the Atherosclerosis Risk in Communities Study³⁵
24
25 showed that elevated plasma hs-cTnT levels are associated with an increased risk of
26
27 non-lacunar ischaemic strokes, and especially cardioembolic stroke, but not with
28
29 hemorrhagic stroke in the general population. Epidemiological data have
30
31 demonstrated that there are differences in incidence rates of stroke subtypes between
32
33 Chinese and western populations. Intracerebral haemorrhage (ICH) accounts for only
34
35 10–15% of strokes in most western populations,³⁶ whereas up to 55% of strokes in
36
37 the Chinese population are due to ICH.³⁷ Although an analysis for ischaemic stroke as
38
39 an endpoint was conducted (data not shown), less than half of all strokes were due to
40
41 ischaemia, and it was impossible to achieve statistical significance.
42
43
44
45
46
47
48
49
50

51 Our study has several limitations. First, cardiovascular treatment has changed
52
53 over time, and it is possible that a higher frequency of the use of medications, such as
54
55 statins and antiplatelet drugs, could have lowered the predictive value of hs-cTnT.
56
57
58
59
60

1
2
3
4 Second, no echocardiographic and coronary artery imaging data were obtained. Thus,
5
6 no causal explanations for the associations among hs-cTnT levels, cardiac
7
8 abnormalities, and outcomes could be provided. Third, the incidence rate of adverse
9
10 events was relatively low in this cohort, and hs-cTnT levels were detected in a
11
12 considerable proportion. This could limit its potential for predicting long-term events.
13
14 Finally, the study population was restricted to Chinese residents of Han origin.
15
16 Extrapolation of the results to other demographic groups should be done with caution.
17
18 The predictive value of hs-cTnT needs to be further validated in other observational
19
20 studies.
21
22
23
24

25 26 **Conclusion**

27
28 In this prospective cohort of a community-dwelling population, we found that
29
30 both baseline cTnT and changes in cTnT, as detected by a highly sensitive assay, were
31
32 independently associated with adverse outcomes. The results suggest that cTnT may
33
34 be an important biomarker in the prediction of mortality and cardiovascular events in
35
36 apparently healthy individuals. Further investigations are warranted to elucidate the
37
38 mechanisms for cTnT release in these individuals and to test whether active
39
40 interventions can reduce the associated risk contributed by elevated troponin levels.
41
42
43
44
45
46
47
48

49 **Contributorship statement:** The manuscript has been read and approved by all
50
51 of the authors. All authors contributed to the intellectual development of this paper.
52
53 Conceived and designed the experiments: Ping Ye. Performed the experiments:
54
55 Wenkai Xiao, Yuan Liu. Analyzed the data: Wenkai Xiao and Yongyi Bai. Wrote the
56
57
58
59
60

1
2
3
4 manuscript: Wenkai Xiao. Supervised data collection: Rui Cao, Fan Wang, Hongmei
5
6 Wu.
7

8
9 **Competing Interests:** The authors have declared that no competing interests
10
11 exist.
12

13
14 **Funding:** This study was supported by grants from the Key National Basic
15
16 Research Program of China (2012CB517503, 2013CB530804) and the Key Science
17
18 and Technology Foundation of China (2012ZX09303004-002) to P Ye.
19

20
21 **Data sharing statement:** The additional unpublished data from the study are
22
23 available. We can share the original data for this research article.
24

25
26 **Acknowledgements** We thank our colleagues at the Department of Laboratory
27
28 Medicine of the PLA General Hospital for their help with biochemical measurements.
29
30 We are also grateful to all study participants for their rigorous work.
31
32
33
34
35

36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

1. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA* 2003;290:898-904.
2. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *JAMA* 2009;302:49-57.
3. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project. *Circulation* 2010;121:

1
2
3
4 2388-97.

5
6 4. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac
7
8 troponin measurement in acute cardiac care. *Eur Heart J* 2010;31: 2197–204.

9
10 5. Bandstein N, Ljung R, Johansson M, et al. Undetectable High-Sensitivity Cardiac
11
12 Troponin T Level in the Emergency Department and Risk of Myocardial Infarction. *J*
13
14 *Am Coll Cardiol* 2014;63:2569-78.

15
16 6. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve
17
18 the prediction of death from cardiovascular causes. *N Engl J Med* 2008;358: 2107–16.

19
20 7. Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T
21
22 and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older
23
24 adults: results from the Rancho Bernardo Study. *J Am Coll Cardiol* 2008;52:450–9.

25
26 8. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T
27
28 and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men.
29
30 *Am Heart J* 2013;166:541-8.

31
32 9. Masson S, Anand I, Favero C, et al. Serial Measurement of Cardiac Troponin T
33
34 Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. *Circulation*
35
36 2012;125:280-8.

37
38 10. Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T and
39
40 secondary events in outpatients with coronary heart disease from the Heart and Soul
41
42 Study. *JAMA Intern Med* 2013;173:763–9.

43
44 11. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-
45
46 sensitivity cardiac troponin T assay. *Clin Chem* 2010;56:254-261.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 12. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating
5
6 equation for chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17:
7
8 2937-44.
9
10
11 13. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for
12
13 the 21st century: statement for healthcare professionals from the American
14
15 Heart Association/American Stroke Association. *Stroke* 2013;44:2064-89.
16
17
18 14. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary
19
20 heart disease in epidemiology and clinical research studies. *Circulation* 2003;108:
21
22 2543-9.
23
24
25
26 15. Oemrawsingh RM, Cheng JM, García-García HM, et al. High-sensitivity
27
28 Troponin T in relation to coronary plaque characteristics in patients with stable
29
30 coronary artery disease; results of the ATHEROREMO-IVUS study. *Atherosclerosis*
31
32 2016;247:135-41.
33
34
35
36 16. Giannitsis E, Spanuth E, Horsch A, et al. High-sensitivity cardiac troponin T and
37
38 N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery
39
40 disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC)
41
42 study. *Clin Chem Lab Med* 2013;51:2019-28.
43
44
45
46 17. Rubin J, Matsushita K, Lazo M, et al. Determinants of minimal elevation
47
48 in high-sensitivity cardiac troponin T in the general population. *Clin Biochem* 2016;
49
50 49:657-62.
51
52
53
54 18. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a
55
56 highly sensitive assay predicts coronary heart disease, heart failure, and mortality in
57
58
59
60

- 1
2
3
4 the Atherosclerosis Risk in Communities Study. *Circulation* 2011;123:1367-76.
- 5
6 19. Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid atrial
7
8 pacing causes troponin T release detectable by a highly sensitive assay: insights from
9
10 a coronary sinus sampling study. *J Am Coll Cardiol* 2011;57:2398-405.
- 11
12
13 20. White HD. Pathobiology of troponin elevations: do elevations occur with
14
15 myocardial ischemia as well as necrosis? *J Am Coll Cardiol* 2011;57:2406-8.
- 16
17
18 21. Røsjø H, Andreassen J, Edvardsen T, et al. Prognostic usefulness of circulating
19
20 high-sensitivity troponin T in aortic stenosis and relation to echocardiographic
21
22 indexes of cardiac function and anatomy. *Am J Cardiol* 2011;108:88-91.
- 23
24
25 22. Kawasaki T, Sakai C, Harimoto K, et al. Usefulness of High-Sensitivity Cardiac
26
27 Troponin T and Brain Natriuretic Peptide as Biomarkers of Myocardial Fibrosis in
28
29 Patients With Hypertrophic Cardiomyopathy. *Am J Cardiol* 2013;112:867-72.
- 30
31
32 23. Ravassa S, Kuznetsova T, Varo N, et al. Biomarkers of cardiomyocyte injury and
33
34 stress identify left atrial and left ventricular remodelling and dysfunction: A
35
36 population-based study. *Int J Cardiol* 2015;185:177-85.
- 37
38
39 24. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures
40
41 of cardiac troponin T using a sensitive assay with incident heart failure and
42
43 cardiovascular mortality in older adults. *JAMA* 2010;304:2494-502.
- 44
45
46 25. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected
47
48 with a highly sensitive assay and cardiac structure and mortality risk in the general
49
50 population. *JAMA* 2010;304:2503-12.
- 51
52
53 26. Sze J, Mooney J, Barzi F, et al. Cardiac Troponin and its Relationship to
54
55
56
57
58
59
60

1
2
3 Cardiovascular Outcomes in Community Populations – A Systematic Review and
4
5
6 Meta-analysis. *Heart Lung Circ* 2016;25:217-28.
7

8
9 27. Lazzarino AI, Hamer M, Gaze D, et al. The association between cortisol response
10
11 to mental stress and high-sensitivity cardiac troponin T plasma concentration in
12
13 healthy adults. *J Am Coll Cardiol* 2013; 62:1694-701.
14

15
16 28. Schnell-Inderst P, Schwarzer R, Göhler A, et al. Prognostic value, clinical
17
18 effectiveness, and cost-effectiveness of high - sensitivity C-reactive protein as a
19
20 marker for major cardiac events in asymptomatic individuals: a health technology
21
22 assessment report. *Int J Technol Assess Health Care* 2010; 26:30-9.
23

24
25 29. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of N- terminal
26
27 pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk as
28
29 assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2015;
30
31 170:1170-83.
32
33

34
35 30. Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-
36
37 terminal pro -B type natriuretic peptide are associated with cardiovascular events
38
39 despite the cross- sectional association with albuminuria and glomerular filtration rate.
40
41
42
43
44 *Eur Heart J* 2012; 33:2272-81.
45

46
47 31. Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury assessed by
48
49 a highly sensitive troponin assay and sudden cardiac death in the community: the
50
51 Cardiovascular Health Study. *J Am Coll Cardiol* 2013;62:2112-20.
52

53
54 32. Hussein AA, Bartz TM, Gottdiener JS, et al. Serial measures of cardiac troponin
55
56 T levels by a highly sensitive assay and incident atrial fibrillation in a prospective
57
58
59
60

1
2
3 cohort of ambulatory older adults. *Heart Rhythm* 2015;12:879-85.

4
5
6 33. Masson S, Latini R, Mureddu GF, et al. High-sensitivity cardiac troponin T for
7
8 detection of subtle abnormalities of cardiac phenotype in a general population of
9
10 elderly individuals. *J Intern Med* 2013;273:306-17.

11
12
13 34. de Lemos JA, deFilippi CR. Prevalence and significance of detectable troponins as
14
15 measured by highly sensitive assays in the general population. *Coronary Artery*
16
17 *Disease* 2013;24:705-9.


18
19
20
21 35. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-Terminal Pro-B-Type
22
23 Natriuretic Peptide, and Incidence of Stroke. The Atherosclerosis Risk in
24
25 Communities Study. *Stroke* 2013; 44:961-7.

26
27
28
29 36. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke
30
31 statistics-2009 update: a report from the American Heart Association Statistics
32
33 Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:480-6.

34
35
36 37. Yang QD, Niu Q, Zhou YH, et al. Incidence of cerebral hemorrhage in the
37
38 Changsha community. A prospective study from 1986 to 2000. *Cerebrovasc Dis.*
39
40 2004;17:303-13.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


A Major adverse cardiovascular events



No. at risk				
Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

95x106mm (600 x 600 DPI)

B Coronary event




No. at risk

Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

84x98mm (600 x 600 DPI)

C Stroke




No. at risk	0	20	40	60
Group 1	679	676	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

99x114mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

D All-cause mortality



No. at risk				
Group 1	679	674	649	344
Group 2	324	318	307	103
Group 3	324	311	285	105
Group 4	172	161	140	45

Figure1. Risk for Cardiovascular Events and All-Cause Mortality by Baseline hs-cTnT Level
Kaplan-Meier survival curves indicating cumulative incidence of MACE (A), Coronary event (B), Stroke (C) and All-cause mortality (D) across baseline hs-cTnT categories. Groups are indicated by colors, P<0.001 for all between-group comparisons by the log-rank test.

113x89mm (600 x 600 DPI)

Supplementary Table1. Characteristics of Study Population between the follow up and lost groups

Characteristics	Baseline population		P value
	Follow up group (n=1499)	lost to follow up group (n=181)	
Demographic			
Age (years)	61.4±11.4	57.6±10.5	<0.01
Male Sex n (%)	629 (42.0)	83(45.9)	0.316
BMI (kg/m ²)	25.6±3.3	25.8±3.4	0.273
Medical history			
Hypertension n (%)	690(46.0)	72(39.8)	0.111
Diabetes mellitus n (%)	292(19.5)	30(16.6)	0.348
Current smoking n (%)	247(16.5)	35(19.3)	0.331
Systolic BP (mm Hg)	132.7±17.0	130.6±16.7	0.136
Diastolic BP (mm Hg)	76.6±10.3	77.8±10.7	0.077
Laboratory values			
FBG (mmol/L)	5.4±1.6	5.3±1.5	0.474
PBG (mmol/L)	8.0±4.2	7.5±3.7	<0.05
Total cholesterol (mmol/L)	5.1±0.9	5.0±0.9	0.321
Triglycerides (mmol/L)	1.8±1.2	1.9±1.1	0.054
LDL cholesterol (mmol/L)	3.0±0.7	2.9±0.6	0.21
HDL cholesterol (mmol/L)	1.4±0.3	1.4±0.3	0.386
Uric acid (μmol/L)	291.4±73.3	276.9±70.8	<0.01
eGFR (mL/min/1.73m ²)	88.9±15.5	92.1±16.0	0.009
NT-proBNP (pg/mL)	41.7(19.8,81.9)	37.4(17.3,73.9)	<0.01
Hs-CRP (mg/L)	2.3 (1.4, 3.5)	2.2 (1.3, 3.4)	0.189
Medication use			
Antihypertensives n (%)	528 (35.2)	55 (30.4)	0.197
Antidiabetic n (%)	189 (12.6)	19 (10.5)	0.415

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Lipid lowering	n (%)	262 (17.5)	29(16.0)	0.625
Aspirin	n (%)	360 (24.0)	37 (20.4)	0.285

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4	
Objectives	3	State specific objectives, including any prespecified hypotheses	5	
Methods				
Study design	4	Present key elements of study design early in the paper	5	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5-6	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7	
Bias	9	Describe any efforts to address potential sources of bias		
Study size	10	Explain how the study size was arrived at		

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8-9
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	9
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-13
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14-16
		(b) Report category boundaries when continuous variables were categorized	15
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	17
Discussion			
Key results	18	Summarise key results with reference to study objectives	18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	22
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49